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Abstract

NON-CANONICAL ROLES FOR STAT1 AND STAT2 IN MITOCHONDRIAL
BIOGENESIS AND FASTING HOMEOSTASIS.
By Jennifer D Sisler
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctorate of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Major Director: Andrew Larner, M.D., Ph.D.
PROFESSOR OF BIOCHEMISTRY AND MOLECULAR BIOLOGY

The signal transducer and activator of transcription 1 (STAT1) and 2 (STAT2) are
primarily activated by interferons and play a central role in orchestrating responses to a
variety of pathogens by activating the transcription of nuclear encoded genes that mediate
antiviral, antigrowth and immune surveillance responses. In addition to their nuclear
effects, we report that STAT1 and STAT2 inhibit the expression of mitochondrial encoded
mRNAs by activating type I interferons (IFNβ) under basal conditions. STAT1-/- livers
also exhibit elevated levels of nuclear encoded components of the electron transport chain

xxii
(ETC). Treatment of wild-type mice with IFNβ inhibits both mitochondrial and nuclear
transcription of the ETC components. The inhibition of mitochondrial encoded
transcription by IFNβ is both STAT1 independent and dependent because it is also seen in
STAT1-/- mice. This inhibitory action of IFNβ on mitochondrial transcription is mediated
by a small pool of STAT1 and STAT2 residing within the mitochondria. This study would
suggest a novel mechanism for STAT1 and STAT2, wherein they negatively regulate
mitochondrial transcription and STAT1 coordinately regulates transcription of both
mitochondrial and nuclear ETC components upon IFNβ stimulation.
PGC1α has been described as the master regulator of mitochondrial biogenesis, and
upon starvation its levels are elevated within the liver to increase mitochondrial biogenesis.
The levels of PGC1α are increased in the STAT1-/- mice basally. However they are not
increased further under starvation. Additionally, we report a novel phenotype of the
STAT1-/- mice that suggests that they have a dysregulation of energy expenditure during
starvation. We see that activation of hormone sensitive lipase which is the rate limiting
step of lipolysis is attenuated in the adipose tissue of STAT1-/- mice and that there is less
lipid accumulation in the livers of STAT1-/- compared to wild-type mice. The mechanism
of STAT1’s role in energy regulation is not fully understood; however, this report would
suggest that STAT1 does play a role within fasting homeostasis that is independent of
IFNβ.

CHAPTER I
Introduction
1.1 Jak-Stat Pathway

Twenty years ago the Janus kinase (Jak) / Signal Transducers and Activators of
Transcription (STAT) pathway was discovered in the labs of Stark and Darnell, involved
in the signaling cascade of interferons [1-3]. The Jak-STAT pathway is conserved through
evolution and has been studied extensively from humans to flies. In mammals, the JakSTAT pathway is activated mainly by cytokines and growth factors that lead to the
regulation of cell proliferation, differentiation, cell migration and apoptosis. Mutations
within this pathway can cause an array of diseases, cancers, and disruptions in immune
responses [1, 4].
Briefly, the signaling cascade is activated by a cytokine or growth factor binding to
its cell surface receptor, which induces the binding of one or two Jaks with that receptor.
The Jaks are activated by transphosphorylation leading to phosphorylation of specific
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2
tyrosine residues on the cytoplasmic domain of the receptor which will provide a docking
site for the STAT proteins through their Src homology (SH2) domains. Once docked, the
Jak protein will then tyrosine phosphorylate the STAT protein, which will cause its release
from the receptor. The activated STAT proteins form homodimers or heterodimers and
translocate into the nucleus. Within the nucleus they bind to specific DNA sequence motifs
known as interferon stimulated response elements (ISREs) or gamma interferon activation
sequence (GAS) elements, which are located within the promoter regions of STAT target
genes [1, 3, 5, 6]. The classical Jak-STAT signaling cascade can be seen in Figure 1.1.
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Figure 1.1 The classical Jak-STAT Pathway

4
1.2 Janus Kinases
Janus kinases (Jaks), are a family of non-receptor tyrosine kinase proteins that are
conserved through evolution from human to drosophila [7, 8]. In mammals, there are four
known Janus kinases: Jak1, Jak2, Jak3, and tyrosine Kinase 2 (Tyk2). Jak1, Jak2 and Tyk2
are ubiquitously expressed whereas Jak3 is mainly expressed within hematopoietic cells
and is highly regulated during cell development. Because of their two kinase domains,
which are unique to this family, Andrew Wilks, who discovered Jak1 and Jak2, named this
family of proteins as Janus kinases after the two faced Roman god Janus. It is also termed
Jak “just another kinase” as well [1, 2, 4, 6, 7, 9].
In humans, Jak1 is located on chromosome 1p31.3, Jak2 is on 9p24, and Jak3 and
Tyk2 are grouped together on 19p13.1 and 19p13.2. In mice, Jak1 is found on
chromosome 4, Jak2 on 19, and Jak3 and Tyk2 are located on chromosome 8 [6]. Jaks are
large proteins with molecular sizes between 120 and 140 kDa [10]. The primary structure
of the Jak members is highly conserved and contains seven Jak homology (JH) domains
that have been labeled 1-7 from the carboxyl terminus to the amino terminus. The JH1
domain is the tyrosine kinase domain that is closely related to the kinase domain of the
epidermal growth factor family of receptors kinases [11]. The JH2 domain is known as the
pseudokinase domain, which was thought to be an inactive kinase domain, but there have
been recent reports stating otherwise. For example, it has been reported by the
Silvennoinen group that the pseudokinase domain within Jak2 negatively regulates the
kinase activity of the protein by phosphorylating Ser523 and Tyr570. This negative
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regulation appears to keep Jak2 inactive in the absence of ligand and it is possible that this
domain also plays a role in regulating Jak2-substrate interactions [12, 13] The amino
terminus domain contains an SH-2 like domain (JH3-JH4), with JH4 being the most
conserved region of the entire Jak sequence [10]. The last two JH domains (JH6-JH7) are a
combined 300 amino acids long comprise the ezrin, radixin, moesin (FERM) domain. This
domain is important in mediating interactions with transmembrane proteins like the
cytokine receptors. It is possible that this domain also interacts with cell surface receptors,
which provides stability to these proteins. It has been seen that this domain interacts with
the kinase domain and positively regulates the catalytic activity [4, 6, 10]. These domains
are illustrated in the schematic of the primary structure of the Jak family proteins in Figure
1.2.
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Figure 1.2 The structure of Jak family proteins [6, 10].
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Because of their size, it has been problematic to determine their 3 dimensional crystal
structure. However, the structure of the kinase domain of each of the Jaks has been
determined which has helped in drug development [11] where they associate with cytokine
receptors. Recent reports have suggested that Jak2 also has the ability to translocate into
the nucleus and directly phosphorylate the histone H3 tail on tyrosine [4]. This study
suggests that Jak2 has the ability to activate gene expression in a STAT-independent
manner. There are also reports that a small fraction of Jak1 and Tyk2

reside within the

nucleus. The idea of this non-canonical nuclear action of the Jak family is still
controversial because it is not clear if wild-type Jak1 and Jak2 are located within the
nucleus. However, if they are present in the nucleus it would provide a new novel role for
the Jak proteins that would be independent of STAT proteins [9].
The Jak family of tyrosine kinases were linked to cytokine receptors using mutant
cell lines that were created to better understand interferon signaling. The first Jak to be
associated with interferon signaling was Tyk2, which identified its ability to restore type
one interferon induced gene expression in Tyk2-negative Ht1080 cells [6]. Shortly there
after, other Jak proteins were shown to interact with cytokine receptors that led to the
understanding of their role in the immune system. Knock-out mice were generated for
each of the Jak family members during the late 1990’s and early 2000’s, and as expected
these mice lack cytokine signaling and have serious disease phenotypes. Table 1.1
summarizes the phenotypes of these knock-out animals. Jak1-/- mice are preinatal lethal.
This is most likely due to the lack of gp130 signaling (IL-6, IL-11, oncostatin M, leukemia
inhibitory factor (LIF), ciliary neurotrophic factor (G-CSF) and IFNs) causing neurological
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defects. From these studies it also appears that Jak1 interacts with cytokine receptors that
have a subunit called a common γ chain (γc), which includes interleukin 2 (IL)-2, IL-4, IL7, IL-9, IL-15, and IL-21 [14-17]. Jak2 knock-out mice are embryonic lethal at day 12.5
due to defects of erythropoiesis [18, 19]. It has been shown that Jak2 will bind to a family
of receptors with the subunit gp130 (as listed above). Jak2 is essential for hormone-like
cytokines such as growth-hormone (GH), prolactin (PRL), erythropoietin (EPO),
thrombopoietin (TPO) and the IL-3 receptor. The functional role of Jak3 was first
discovered in humans with autosomal recessive severe combined immunodeficiency
(SCID) where it was identified that mutations within either Jak3 or γc causes the failure of
immune-cell development and function. Once this discovery was made, the Jak3 knock out
mice were generated and unsurprisingly showed the same phenotype [15, 16]. Tky2 is
essential for type I interferon signaling along with Jak1 whereas it is not necessary for type
II interferon signaling [18, 19]. Since Tyk2 is important in both type I interferon and IL-12
signaling, Tyk2 null mice have enhanced Th2 immune reponse [20, 21]. As can be seen
from the knockout mice, the members of the Jak kinase family are essential for growth,
cell development and immune responses. There has also been extensive research done on
mutations in the Jak proteins that occur during different diseases [22] leading to
inflammatory diseases, erythrocytosis, gigantism and an array of leukemias [1].
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Table 1.1 The conclusions drawn from studying the Jak family knock-out mice
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1.3 Signal Transducers and activators of transcription

Signal Transducers and Activators of Transcription (STAT) family members are
transcription factors that regulate many aspects of a cell’s function such as proliferation,
differentiation, migration, and apoptosis [1]. Mutations or the lack of expression of these
proteins can cause tumor formation and invasive metastasis [4]. This family was so named
because the proteins can transduce a signal and are transcription factors. Their name was
later shortened to STATs because their activation occurred quickly as in “STAT” by Dr.
Darnell’s wife [3].
In mammals there are seven known STAT family members: STAT1, STAT2,
STAT3, STAT5a, STAT5b and STAT6. In the classical Jak-STAT pathway, STATs are
unphosphorylated within the cytoplasm and upon activation (tyrosine phosphorylation)
dimers are formed which then translocate to the nucleus [1, 2, 5, 7, 23, 24]. The STAT
proteins contain between 700 and 900 amino acids with a molecular weight ranging from
80-113 kDa [16, 25]. STAT proteins are located in clusters on chromosomes in the murine
genome: STAT1 and STAT4 are located on chromosome 1, STAT2 and STAT6 are
located on chromosome 10 and STAT3, STAT5a and STAT5b are located on chromosome
11 which would suggest that they have a common ancestral gene [7]. The genes encoding
STAT proteins contain multiple exons and alternative splicing occurs for STAT1, STAT3,
STAT4 and STAT5 leading to a Beta isoform [26-29]. Interestingly, these beta isoforms
are considered to be negative regulators of the Jak-STAT pathway and have the ability to
activate a subset of genes that are not regulated by the full length STATs [26, 29-32]. The
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expression levels of the STAT proteins vary within tissues. STAT1 is widely expressed
with the highest levels in heart, thymus and spleen. STAT4’s expression is mainly limited
in testis, thymus and spleen. STAT5a and STAT5b are expressed in muscle, brain,
mammary gland and secretory organs such as the seminal vesicles and salivary gland.
STAT2, STAT3 and STAT6 are all ubiquitously expressed [33]. The crystal structure of
the STAT proteins has been determined which led to a better understanding of the domains
located within the primary structure [34, 35]. The STAT proteins share six conserved
domains. These include a N-terminal regulatory domain (NTD), a coiled-coiled domain
(CC), a DNA-Binding domain (DBD), a Src Homology 2 domain (SH2), a linker domain
(LD), and a C-terminal transactivation domain (TAD), which can be visualized in Figure
1.3.
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Figure 1.3. The primary structure of STAT family proteins.
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The first 120-150 amino acids are known as the N-terminal domain (NTD) and it has
been reported to play a role in receptor recognition, oligomerization of STAT dimers,
interaction with co-activators like CBP/p300, and nuclear translocation [36-39]. From
studying the crystal structure of the NTD is made up of several helices that form a hooklike structure that allows for protein-protein interactions [40].
Next to the NTD, located approximately between residues 150 to 320, is the coiledcoil domain (CC). This domain is mainly hydrophilic and contains four alpha-helices,
which allows for protein-protein interactions. STAT proteins are able to interact with other
alpha-helical proteins such as other STATs, p48/IRF-9, c-Jun, N-myc [41], through this
domain. It has also been reported that the CC domain is important for receptor binding,
tyrosine phosphorylation and nuclear import [42, 43].
The DNA-binding domain (DBD), located roughly between 320 and 490, is
important for the STATs to bind DNA. The 3D structure of this domain is made up of
beta-barrels that fold upon themselves, which is similar to the DBD seen in other
transcription factors such as NF-ΚB or p53 [35]. The DBD domain will recognize two
different DNA sequences within promoter regions of genes that are controlled
transcriptionally by STAT signals. The first is known as the interferon-stimulated response
element (ISRE) with the sequence motif as 5‘-AGTTCNNTTTCNC/T-3’, where N equals
any base [44, 45]. The second sequence motif that is recognized by STAT heterodimers or
homodimers is known as the interferon-gamma activation sequence (GAS) element (5’TTNCNNNAA-3’), where N equals any base [46, 47].
The linker domain (LD) is a highly conserved domain within the STAT family and it
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is located between residues 490 to 580. While the function of this domain is not well
understood, there have been some studies that demonstrate its importance. For example, it
was shown that in STAT1 this domain is important for stability after Interferon treatment
[48] and that it is also important for STAT3 to interact with GRIM-19 in the innermitochondrial membrane [49].
The SH2 domain that resides between amino acids 580 to 680 is the most conserved
domain within the STATs. Structurally it consists of a pocket formed by two alpha helices
separated by anti parallel beta sheets. The variability within this domain is what facilitates
the selectivity of STATs in binding to their cytokine receptors [7]. At the base of the
pocket there is a conserved arginine that facilitates interaction with the phosphate group of
tyrosine phosphorylated proteins. This domain is most important because it allows for
STAT dimers to form, which is essential for STAT signaling. There is also a tyrosine
residue located at the C-terminus end of the SH2 domain that is phosphorylated by Jaks
and other tyrosine kinases, which is recognized by other SH2 domains and is necessary for
the transcriptional function of STAT proteins [50].
The transactivation domain (TAD) domain within STAT proteins is the least
conserved domain and varies in length from 38 to 200 amino acids. Despite the variability,
it is extremely important for the transcriptional activity of STAT proteins as this domain
drives the interaction of STATs with other activators and co-activators. STAT1, 3, 4, 5A
and 5B have a conserved serine residue that is located within this domain that is essential
for maximal transcriptional activity [51-54]. The kinase that phosphorylates this serine is
still not completely understood, however, it is proposed that this phosphorylation may

15
change the affinity of these STATs with other transcriptional regulators such as MCM5,
BRAC1, or CBP/p300 [7, 55-57].
The biological function of STAT proteins was determined using knock out mouse
models. The summary of the phenotypes of the knock out mice generated is in Table 1.2.
Briefly, STAT1 knock out mice were generated in the Schreiber and Levy labs in 1996 and
it can be concluded from the experiments that followed that STAT1 plays a key role in
both type I and type II interferon signaling. These studies also demonstrated that STAT1
knock out mice are both viable and fertile, but these mice are immunosuppressed and are
susceptible to viral infections and tumors [58, 59].
STAT2 knock mice were generated in Schindler’s lab in 2000 and they established
that STAT2 knock out mice are both viable and fertile. However they exhibit defects
within their immune response including increased vulnerability to viral infections. This is
most likely due to the fact that STAT2 knock-out mice have a loss in their type I interferon
signaling [60].
STAT3 knock out mice were unable to be generated because they are embryonic
lethal and die on E7 [17]. Through alternative splicing, STAT3 has two different isoforms,
alpha and beta. STAT3-alpha deficient mice survive embryonic development; however,
they show perinatal lethality due to respiratory failure and appear to be cyanotic at the time
of death [31, 61]. At the same time, STAT3-beta knock out mice are viable and fertile, but
they have delayed immune responses. To fully understand STAT3’s role within specific
tissues in adult mice, conditional knock out animals were generated [17, 62-64].
STAT4 knock out mice were generated in 1996 in the Grusby lab [65].These mice

16
are both viable and fertile however, they were susceptible to viral infections that elicit a
Th1 response. The STAT4 knock out mice also have impaired Th1 differentiation due to a
loss in IL-12 signaling [66].
STAT5a was first discovered as a mammary gland factor so it was no surprise that
when the knock out mouse was generated it had a defect in mammary gland development.
These mice developed normally and are fertile, although pregnant female mice are unable
to lactate. These defects are most likely due to impaired prolactin signaling [67, 68]
STAT5b, which is over 90% similar to Stat5a, is both viable and fertile. STAT5b does not
play a role within mammary gland development and cannot compensate for STAT5a.
However when the STAT5b knock out animals were generated they had a loss in growth
hormone responsiveness. This defect causes a loss of multiple, sexually differentiated
responses [69].
STAT6 mutation cell lines showed that STAT6 is activated by both IL-4 and IL-13.
Therefore when the knock-out mouse was generated, it was both viable and fertile but had
a similar phenotype to the IL-4 knock-out animal. The blockage of IL-4 signal transduction
due to the absence of STAT6 leads to a failure of development of Th2 cells as well as
impaired IL-4 dependent class switching to IgE in B cells [70-73].
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Table 1.2. Phenotypes of STAT family knock out mice [24].
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1.4 Non-Classical roles for STAT proteins

In the past twenty years, the Jak-STAT pathway has been studied extensively and it
is clear that the classical Jak-STAT pathway plays a key role in many biological functions.
Recently however, several studies have been published that Jaks and STATs have other
functions in addition to their ability to activate immediate early genes by cytokines.
George Stark’s lab has led the field in studying unphosphorylated STATs and how they
function within the cell [74]. It has been reported that un-phosphorylated STATs (USTATs) translocate to the nucleus and activate a subset of genes that are independent of
genes activated by phosphorylated STATs [75]. It has also been reported that U-STAT3
has been found in high levels in many types of tumors, which can contribute to enhanced
tumorigenesis [76]. There have also been reports that drosophila STAT (STAT92E) has the
ability to translocate into the nucleus when unphosphorylated and associate with
heterochromatin to maintain it in its transcriptionally inactive state [77].
STATs have also been shown to play a part in non-canonical pathways within the
mitochondria. It has been reported that both STAT3 and STAT5 translocate to the
mitochondria. The first reports that STATs were located in the mitochondria were
published in 2009 from the Levy and Larner labs [78, 79]. It was reported that
mitochondrial located STAT3 (mito-STAT3) plays a role in controlling respiration by
interacting with Complex I of the electron transport chain, while also playing a role in Ras
transformation of cells. It appears that this function of mito-STAT3 requires
phosphorylation on Serine 727. Interestingly, mito-STAT3 does not need the conserved
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tyrosine, the SH2 domain or the DBD domain to function, unlike nuclear STAT3, which
needs both [78-80]. As for STAT5’s role within the mitochondria, it has been published
that it translocates into the mitochondria upon stimulation with IL-2. Within the
mitochondria, it interacts with the E2 component of the mitochondrial pyruvate
dehydrogenase complex. STAT5 can bind to the regulatory D-Loop of the mitochondrial
genome in vitro, which suggests that mito-STAT5 has the ability to regulate mitochondrial
transcription [80, 81].

1.5 Regulation of the Jak-STAT Pathway

The Jak-STAT pathway is highly involved in many biological processes and the loss
of this regulation of the Jak-STAT pathway can lead to tumorigenesis or chronic
inflammation [23]. This pathway is regulated by several different mechanisms including:
tyrosine phosphatases, receptor internalization, proteasomal degradation of signaling
adaptor molecules, soluble receptor antagonists and specific inhibitors for each step of the
pathway [23, 33, 50]. The suppressor of cytokine signaling (SOCS) proteins consists of
eight members, CIS and SOCS1-7, that serve as a negative feedback loop for the JakSTAT pathway. The transcription of the SOCS family members are STAT dependent, and
are important for inhibition of the Jak kinase activity as they serve as competitive
inhibitors to the STAT proteins for receptor binding [7, 23, 82]. Another aspect of
regulation occurs at the level of tyrosine phosphatases. Tyrosine phosphatases reported to
mediate Jak/Stat signaling include: the SH2 domain-containing phosphatase (SHP) 1,
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SHP2, PTP1B, T-cell PTP (TC-PTP) and CD45. These proteins dephosphorylate the
cytokine receptors, Jaks, and STATs. STAT proteins can be dephosphorylated in the
cytosol or in the nucleus to inhibit the Jak-STAT signaling pathway [33, 50]. Another
family of proteins that were discovered to regulate the Jak-STAT signaling pathway are
known as Proteins that inhibit activated STATs (PIAS). These proteins interact with
tyrosine phosphorylated STAT proteins and block their ability to bind DNA in vitro. It has
also been shown that these proteins have other biological roles that are independent of
STAT proteins [50, 82]. Through these different mechanisms the regulation of the JakSTAT pathway is kept in check and the biological equilibrium within the cell is preserved.

1.6 Signal Transducers and Activators of Transcription (STAT) 1

STAT1 was the first of the STAT family proteins to be discovered. STAT1 was first
discovered in the signaling cascade of type I interferons (INFα/β) and has since been
shown to play a key role in a wide range of biological activities. There are two different
isoforms termed STAT1α and STAT1β. STAT1α 91kDa while STAT1β is alternatively
spliced and does not have a portion of the C-terminus and measures at 84kDa [3, 83]. For
full transcriptional activation of STAT1, tyrosine 701 and serine 727 need to be
phosphorylated. Tyrosine 701 is phosporylated by Jaks; Serine 727 has been reported to be
phosphorylated by a number of kinases such as ERK1/2, p38α, CAMKII, and PKCδ [84].
Interestingly, the STAT1β isoform is lacking this key serine 727 site and it has been
reported that it behaves as a dominate negative for STAT1α, by inhibiting the actions of
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STAT1α, along with the other truncated forms of STAT proteins [33].
It has been shown that STAT1 is regulated through post-translational
modifications. One of the most important ways to inactivate STAT1 is through
phosphatases that target the tyrosine and serine sites. From several studies, it is understood
that this can occur both in the nucleus and in the cytosol [50]. There have been other
reports showing that STAT1 can be ubiquinated but this is still controversial [85]. STAT1
can also be acetylated on lysine 410 and 413, which allows cross talk between the NF-KB
and Jak-STAT pathways [86]. Arginine 31 can be methylated which increases DNAbinding that enhances STAT1 dependent IFN responses [87]. Another mechanism that
regulates STAT1 activity is that lysine 703 which can be both ISGylated and SUMOlated,
both of which play a key role in the pro-apoptotic pathway [88-90]. Figure 1.4 shows all
of the possible post translational modifications of STAT1α and STAT1β.
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Figure 1.4 (A) STAT1α (B) STAT1β primary structure with post translational
modifications
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One of the main characteristics of STAT1 is that it is pro-apoptotic, and it can exert
this activity by transcriptional dependent and independent pathways. STAT1 has the ability
to induce transcription of caspases along with death receptors and ligands. It also has the
capability of being a negative regulator of anti-apoptotic genes such as BCL-xL [83].
STAT1 can also enhance the expression of p21waf, which can inhibit the cell cycle and
lead to apoptosis [91]. In STAT1 null U3A cells, caspases are constitutively active, which
would suggest their activation is independent of STAT1 [92, 93]. It has also been shown
that STAT1 null cells are more resistant to agents that cause apoptosis. STAT1 has been
reported to play a role in apoptosis during ischemia in the heart, brain and liver; however,
for this to occur STAT1 has to be phosphorylated on both tyrosine 701 and serine 727 [94,
95]. Because of STAT1’s apoptotic role, it is no surprise that animals lacking STAT1 are
more susceptible to tumor formation in comparison to wild-type mice. It can be concluded
from these studies that STAT1 acts not only as a pro-apoptotic factor but also as a tumor
suppressor [96-98]. It mainly does this through its transcriptional function, which is
stimulated through the interferon signaling cascade. The inhibition of cell growth is mostly
due to the regulation of genes involved in cell cycle control such as p21waft1 and p27kip1,
which are cyclin dependent kinase (CDK) inhibitors. STAT1 also has the ability to
negatively regulate cyclin A, B, D2, D3, and E which all play a role within the cell cycle
[84]. STAT1 can also repress the transcription factor c-myc, a key regulator of cell
proliferation, and by inhibiting its expression, STAT1 further inhibits cell growth. In
contrast, there have been other reports that show STAT1 has the ability to promote tumor
growth [82, 84], which suggests that STAT1’s biological role within a cell is more
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complicated than originally thought.
From studies done with the STAT1 knock out mouse another function of STAT1
became apparent; that it has an essential role in the immune response to viruses, bacteria
and parasites. STAT1 is important in every step of the processing and presentation of
antigenic peptides by the major hisocompatibility complexes [84]. STAT1 triggers an
immune response through activation of many anti-viral genes such as interferon regulatory
factors (IRFs) and interferon stimulated genes (ISGs). STAT1’s importance in the immune
system is further validated by the fact that STAT1 knock out animals are susceptible to and
often die from viral infections. This has also been found to translate into humans who are
highly sensitive to mycobacterial infections have mutations within STAT1 [99-101].
To conclude, STAT1 plays a key role in the anti-viral, anti-proliferative and proapoptotic pathways within a cell. However, there have been a number of other reports that
point to the emergence of STAT1 as a player in systems outside of its traditional role. For
instance, it has been suggested that STAT1 may affect the maintenance of immunological
self tolerance and in joint inflammation within the model systems [82]. It has also been
suggested that STAT1 plays a role in positively regulating a subset of enzymes of the
glycolysis pathway in cancer suggesting that it may play a larger role other than in the
immune system [102]. From these studies, it is clear that not all is known about the role of
STAT1 within the cell and it will be of interest to further study STAT1 in other nonclassical mechanisms.

25
1.7 Signal Transducers and Activators of Transcription STAT 2

STAT2 was the second family member to be found and it was purified from the
interferon stimulated gene factor 3 (ISGF3) complex. STAT2 is a 113kDa protein that
mainly resides within the cytosol. STAT2 is activated through type I interferons which
leads to its translocation to the nucleus to regulate responses of interferons. Interestingly, it
has been shown that un-phosphorylated STAT2 is located within the nucleus. It is still
unclear the functional reason STAT2 is located within the nucleus however there was one
study that showed that STAT2 binds to the promoter of ISG genes under unstimulated
conditions. After stimulation, STAT2 dissociates from these promoters and the genes are
then transcriptionally up-regulated. This would suggest that STAT2 has the ability to be
both a negative and a positive regulator of transcription [103].
The crystal structure of STAT2 has yet to be determined, but when comparing
STAT2 to the other structures that have been solved, such as STAT1, it is clear that
STAT2 has the same domains and properties as other STAT proteins. One interesting
finding was that the TAD domain of STAT2 has a portion that is not homologous to any
other STAT family member, which will be of interest in later studies. While there are
conflicting reports about whether activated STAT2 binds DNA [103]. Figure 1.5 shows
the domains of STAT2 along with its sites of possible post-translational modifications.
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Figure 1.5 STAT2 primary structure with post translational modifications
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STAT2 protein levels can be up regulated by stimulation with type I interferons. Like
the other STAT proteins, STAT2 can be tyrosine phosphorylated on the conserved tyrosine
site, Tyrosine 690 in humans and Tyrosine 698 in mouse [104-106]. One post translational
modification that occurs in STAT2 is acetylation on Lysine 390, which leads to
destabilization of antiparallel STAT1:STAT2 heterodimers [103]. STAT2 can form several
different dimers to allow for transcriptional regulation including: STAT2:IRF9, STAT1:USTAT2:IRF9, STAT1:STAT2, and STAT1:STAT2:IRF9. Some of these dimmers have the
ability to bind to ISRE and/or GAS elements [103] and this is summarized in Figure 1.6.
Inactivation of STAT2 is much like the other STATs. It is dephosphorylated by a yet to be
identified tyrosine phosphatase. The G protein Ras can also negatively regulate STAT2.
STAT2’s transcriptional regulation was first shown to be dependent on STAT1 and
type I interferon signaling; recently however, there have been studies demonstrating that
STAT2 can act independently of STAT1. In several studies it has been shown that using a
STAT1 null system that has been infected with various viruses or bacteria, a subset of
genes can still be activated to maintain an immune response [107-111]. There are also a
few reports suggesting that STAT2 has the ability to promote an anti-viral response that is
independent of STAT1 [103]. Interestingly, in humans certain viruses have the ability to
impair STAT2 function and prevent interferon signaling from mounting an immune
response in humans. The same has not been shown to be true in mice. Lastly, STAT2 is
also a key player in the pro-apoptotic effects of type I interferons.
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Figure 1.6 STAT2 transcriptional complexes [103].
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1.8 Interferons and Interferon Signaling

Interferons are a family of cytokines that were discovered in 1957 by Isaacs and
Lindenmann [112]. They are only found in vertebrates and are all structurally similar with
their main functions being antiviral and antiproliferative effects, and modulation of
immune responses [113, 114]. Interferons are secreted from almost all cell types but are
mainly secreted from immune cells upon viral infection [76, 113, 115]. It has also been
reported that under normal conditions, the basal levels of IFNα/β are important for
maintaining equilibrium within a cell [116]. All interferons are clustered on chromosome 9
[115]. There are three different sub-families of interferons: Type I interferons (IFNα,
IFNβ, and IFNω), Type II interferons (IFNγ) and the newest subset, Type III interferons
(IFNλs or IL28/29) [113-115]. Interferons have been used as treatment for certain viral
infections, multiple sclerosis and cancer [76].
Type I interferons (IFNα/β) bind to a cell surface receptor composed of two subunits,
interferon alpha receptor (IFNAR) 1 and IFNAR2. IFNAR1 is a 110kDa protein and
IFNAR2 can be alternatively spliced into a long form, IFNAR2a that is 90-100kDa and a
short form, IFNAR2b, of 51kDa. These receptors are widely expressed in different types of
cells and are heavily expressed in immune cells. IFNα/β binds mainly to IFNAR1 and
IFNAR2b which have Tyk2 and Jak1 constitutively bound to their intracellular domains
respectively [115]. IFNα/β binds to the IFN receptor leading to transphosphorylation and
activation of the Jaks. Subsequently STAT1, STAT2, STAT3 and STAT5 are
phosphorylated [76, 113-115]. STAT1 and STAT2 form homo or heterodimers, which
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bind with interferon regulatory factor 9 (IRF9) to form the complex interferon stimulated
gene factor 3 (ISGF3). This complex translocates to the nucleus and binds to interferon
stimulated response elements (ISRE), which allows for transcription of genes that are
important for the antiviral, antigrowth, anti-proliferative, and anti-tumor response of the
cell [76, 115]. The signaling cascade for Type I interferons is shown in Figure 1.7.
Type II interferons (IFNγ) only bind to the interferon gamma receptor, composed of
two subunits IFNGR1 or IFNGR2, which are 90kDa and 62kDa proteins respectively.
These receptors, like type I receptors, are widely expressed and signal through the JakSTAT pathway. Jak1 and Jak2 bind to IFNGR1 and IFNGR2 respectively, which will then
phosphorylate STAT1. STAT1 forms a homodimer which translocates into the nucleus and
binds to Gamma Activated Sequence (GAS) elements within specific gene promoters [1, 2,
7, 117, 118]. The main function of IFNγ is signaling via STAT1 which has been shown
using STAT1 knock out mice therefore, IFNγ is promoting antiviral, antiproliferative and
antigrowth signaling within the cell. Interestingly, unlike Type I inteferons that are
produced by viral infected cells, IFNγ is secreted by activated T cells and NK cells. The
signaling cascade for IFNγ is outlined in Figure 1.7.
Type III interferons (IFNλ) were discovered in 2003 by two independent groups
[119, 120]. IFNλ is structurally distinct from type I or type II interferons and and bind to
their own distinct receptors known as IFNλ-R1 or IL-10R2 [114]. IFNλ, however, activates
the same antiviral response as type I interferons which is also mediated by ISGF3. Studies
are in progress to fully understand their signaling mechanism, but what is known is shown
in Figure 1.7.
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Figure 1.7: Type I, II, and III interferon signaling cascades [121].
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1.9 Type I Interferon inhibition on Mitochondrial Transcription

In the 1990’s, two groups published that treating cells with IFNα/β caused a decrease
in mitochondrial-encoded mRNAs. The first group using a cDNA library from L929 cells
either untreated or treated with IFNα/β, showed that mitochondria encoded mRNAs were
negatively regulated. They further showed that this inhibition could be blocked by pretreating the cells with cycloheximide, which blocks nuclear gene translation, suggesting
that interferon signals through a nuclear protein to inhibit mitochondrial encoded gene
expression. It was also concluded that interferon also inhibited synthesis of mitochondrial
encoded proteins. It was shown that there was selectivity in this signaling pathway because
IFNγ did not decrease mitochondrial encoded gene expression [122, 123].
Rubin’s group published a paper in the late 1990s showing the same negative effect
on mitochondrial encoded mRNAs by interferon; however, they used Daudi cells which
are a human Burkitt’s lymphoma cell line. Daudi cells were important to use because there
are different lines that are resistant to IFNα/β allowing the group to show that the degree of
suppression correlates with the sensitivity of the cells to the antiviral action of interferons.
They were also able to show that for this inhibition to occur protein synthesis is needed but
not DNA synthesis. Rubin’s group also concluded that the suppression was due to a
decrease in transcription rather than the stability of the mitochondrial encoded mRNAs
[124].
When the function of the mitochondria were tested within the Daudi cells treated
with IFN α/β , they saw a decrease in the activity of the electron transport chain leading to
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a decrease in cellular ATP. To further show that this inhibition was due to interferon
signaling, they tested Daudi cells that were resistant to interferons and no inhibition of
mitochondrial RNA expression was observed when treated with in IFN α/β [123].
After these reports were published, another group showed that the decrease in
mitochondrial encoded mRNAs was simply due to a decrease in the nuclear encoded
mitochondrial transcription factor (mtTFA) [125]. These reports all suggest a novel
mechanism for interferons to signal within the cell and further understanding of how and
why the cell allows for this inhibition would be of interest for multiple reasons such as
drug development for diseases that currently use interferon as treatment.

1.10 Mitochondria

Mitochondria are known as the power house of the cell because of their important
role in producing energy. Mitochondria play key roles in energy homeostasis, metabolic
signaling and apoptosis. The shape, size and number of mitochondria in specific tissues is
dependent on the energy demand of that tissue. For example, tissues with high energy
demand such as Brown Adipose Tissue (BAT), slow twitch muscle, heart and liver all have
a large number of mitochondria per cell. It is also important that the regulation of
mitochondrial biogenesis and function is heavily controlled among tissues to allow for
efficiency of energy production [126].
More than 3,000 proteins are components of the mitochondria [127]. In addition,
mitochondria are found in eukaryotic organisms contain their own circular, closed genome
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that is about 16.5 kb and consists of both a heavy strand and a light strand. The
mitochondrial genome is quite efficient since it does not contain any introns.
Mitochondrial DNA encodes 37 genes including 22 tRNAs, 2 rRNAs, and 13 mRNAs. The
13 mRNAs encode regulatory components of complexes I, III, IV, and V of the electron
transport chain, while the remaining subunits of the electron transport chain are nuclear
encoded [128, 129]. The mitochondrial genome is depicted in Figure 1.8. There is one
regulatory region in the mitochondrial genome known as the D-Loop where transcription is
started bidirectionally from both the heavy and light strand (see Figure 1.8).
Mitochondria, contain one transcription factor that regulates transcription, known as Tfam.
A negative regulator of mitochondrial transcription has been described known as MTERF
and it also binds to the D-Loop [130].
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Figure 1.8 Mitochondrial genome and transcriptional factors of mitochondria [131].
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Proteins that are needed for mitochondrial import, respiratory assembly, enzymes
needed for transcription and replication are nuclear encoded [132]. The promoters of
nuclear encoded mitochondrial RNAs have heterogeneous transcriptional initiation sites
and contain regulatory regions that are usually complex and promoter-specific. This
suggests that the regulation is complicated and has several layers. There are two
transcription factors that play a key role in the coordinate regulation nuclear encoded
RNAs that synthesize mitochondrial proteins known as Nuclear Respiratory Factor 1 and 2
(NRF1 and NRF2) [133-135]. To add another level of complexity for the regulation of
nuclear encoded mitochondrial genes, there are co-activators that work with NRF1 and
NRF2 to alter the gene expression among different cell types. Figure 1.9 shows the
transcriptional regulation of nuclear encoded mitochondrial genes.
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Figure 1.9 Transcriptional regulation of nuclear encoded mitochondrial genes [133].
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One of these co-activators that plays an important role in promoting mitochondrial
biogenesis is PPARγ co-activator 1 alpha (PGC1α). PGC1α is the master regulator of
mitochondrial biogenesis. It is widely expressed within tissues that are highly oxidative
such as Brown Adipose Tissue (BAT), slow twitch muscle fibers, heart, brain and liver
[136]. After the discovery of PGC1α by the Spiegelman lab, the discovery of other
members of this family was found: PGC1β and PGC-1 related coactivator (PCR) [137].
Extensive work has been done on PGC1α and it has been shown that several metabolites
can affect the activation of PGC1α such as fatty acid activating PPARs or Insulin
activating AKT and FOXO. It has been shown that PCG1α is also post translationally
modified [138]. For example, it has been shown that p38 MAPK, AMPK, Cdk7, PRMT1,
SIRT1 and GSK-3β can modify PGC1α protein which will then act as a positive feed back
mechanism to continue transcription. However it is also possible for the protein to be
modified in a negative manner by AKT, GCNs, MYBBP1A which will decrease protein
levels and lead to less transcriptional activity [136].
Mitochondrial biogenesis is a long term adaptive response by the cell to a stressful
condition such as fasting or cold exposure [139]. If the cell requires a short energy burst,
mitochondria up regulate certain genes that are needed to increase the amount ATP
produced, but this does not require biogenesis to occur. It is also possible for the cell to
increase mitochondrial function, which again would not require new mitochondria. For
biogenesis to occur it is a fairly extensive job for the cell because genes are transcribed,
translated and then imported into the mitochondria; therefore this process is the last option
for the cell when energy is needed [135]. These processes are highly regulated and tissue
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specific.
The function of mitochondria and mitochondrial biogenesis is tissue specific and is
important in many of the metabolic processes; therefore it is important to understand fully
the mechanisms that are governing these changes [135].

1.11 Metabolic States of Starvation

In any metabolic process, the caloric intake is extremely important and the main
tissue that this affects is the liver. During either fed or starved conditions, the most
important factor to a mouse or a human is to maintain glucose homeostasis in order to have
a constant blood glucose level [140]. To understand the metabolic changes that occur
during starvation, it is first important to understand the metabolic processes of the fed
state.
After feeding, insulin is secreted by β cells in the pancreas, which is stimulated by
high glucose levels and the parasympathetic nervous system. Once insulin levels are high
in the blood stream, it signals the liver to uptake glucose through Glucose transporter 2
(GLUT2) that increases the enzymes that are part of glycogenesis such as glucose 6
phosphate. Once glycogen is made it is stored within the liver for later use when the
glucose levels have been depleted. Also when blood glucose levels are high the muscle and
the adipose tissue are able to uptake glucose. In the muscle, glycogen is stored for later use
but unlike the liver, it is unable to convert the glycogen back to glucose for translocation to
other tissues. Also in the muscle, insulin signals stimulates uptake of branched-chain
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amino acids that allows for the build up of muscle protein. In the adipose tissue glucose
serves as the building block for glycerol 3-phosphate, which is needed to make
triacylglycerols that are stored for later use. At the same time during fed conditions, insulin
and the uptake of glucose signals to these specific tissues to inhibit the degradation of
protein, gluconeogenesis, and glycogenolysis [141].
Once glucose levels have been depleted from the blood stream, the body goes into a
fasting state. During this time, both insulin and glucose levels drop in the blood that signals
for glucagon to be secreted from α cells of the pancreas. Within the liver, glucagon signals
for the breakdown of glycogen through glycogenolysis and the inhibition of glycogenesis
by activating cAMP. However at the same time, gluconeogenesis is activated under these
conditions and decreased levels of fructose 2, 6 bisphosphate, shut down glycolysis.
Glucagon also has the ability to inhibit fatty acid synthesis through decreasing the
production of pyruvate. Glucose that is generated by the break down of glycogen in the
liver is then transported into the blood stream for use by other tissues. However, there is
also glycogen storage within the muscle that is used by the muscle for energy once blood
glucose levels are depleted [141]. If fasting continues and the body has diminished all of
the glycogen stores, then the body will start breaking down fat to use as energy.
Triglycerides are stored within adipose tissue and are broken down and released into the
blood stream to travel to the liver to generate glucose for all other tissues. The breakdown
of the lipids into free fatty acids is known as lipolysis and one of the key enzymes that
does this is known as hormone sensitive lipase (HSL) [142, 143]. This process is heavily
regulated and is dependent on metabolite signaling [144]. After the body has depleted the
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fat stores and the body still has not gained outside nutrients, the body will start to break
down proteins to use as fuel [141]. This is the last resort of the body and only happens
under emergency conditions.
Within the liver, many of the metabolic pathways are activated during starvation and
the mitochondria play a key role in these processes. It has been well documented that
within the liver PGC1α is increased upon fasting conditions because of the increased levels
of glucagon signaling through cAMP and CREB [145]. Under these conditions PGC1α is
post-translationally modified by p38 MAPK in muscle, BAT and liver. In the liver, this
modification is necessary for fasting conditions. PGC1α can also be modified in a similar
manner by free fatty acids, which are released following lipolysis [144]. Within the liver,
PGC1α associates with several transcriptional factors such as Hepatocyte nuclear factor 4α
(HNF4-α) or FoxO1 to increase the expression of gluconeogenic enzymes during fasting
conditions [129]. As can be seen from these studies, PGC1α is a key protein that is needed
to regulate mitochondrial biogenesis and function in the context of gluconeogenesis, fatty
acid synthesis and oxidation, and glycolysis [146].

1.12 Current Study

My studies focus on the actions of STAT1 and STAT2 within the mitochondria and the
effect STAT1 has upon metabolic processes either under basal conditions or under stress
such as starvation. There have been reports suggesting that STAT1 plays a role in
regulating metabolic processes in cancer, however, there have not been any reports of the
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actions of STAT1 during homeostasis [102]. It is of interest to study the effect of STAT1
on these metabolic pathways but also the importance of basal levels of IFNβ within the
organism. This study is important because the results allow us to understand a novel action
of STAT1 and STAT2 within the mitochondria. Also it would suggest that STAT1 is
important in cellular processes other than anti-viral, anti-growth and pro-apoptotic
pathways.

Chapter II
Materials and Methods
2.1 Materials
2.1.1 Antibodies

STAT1 antibody was purchased from BD Transduction (Cat# 610186); Antibody
recognizing PY701 Stat1 polyclonal was purchased from Cell Signaling (9171S). COX1
(MS404) and GRIM-19 (MS103) antibodies were purchased from Mitoscience. Porin was
bought from Calbiochem (529532). Tubulin was purchased from Sigma (T6034) and
cytochrome c was bought from BD Pharmingen (S56433). PYSTAT2 antibody (T689) was
purchased from Millipore (Billerica, MA). Hormone sensitive lipase (HSL) (4107) and
Phospho-HSL (serine563) (4139) were purchased from cell signaling. The polyclonal
STAT1 [147] and STAT2 [148] antibodies were affinity purified with the help of Dr.
Daniel Conrad lab (Virginia Commonwealth University, Richmond, VA). The monoclonal
PY701 Stat1 (M135) was purchased from Abcam Inc (Cambridge, MA). Rabbit polyclonal
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IgG antibody (2729S) was purchased from Cell Signaling (Danvers, MA).

2.1.2. Reagents

Murine Interferon Beta (IFNβ) was a gift from Dr. Darren Baker from Biogen idec
(Cambridge, MA). Murine Interferon Gamma (INFγ) was purchased from PeproTech
(315-05).
All chemicals used during this project were purchased from Sigma Aldrich (St. Louis,
MO).

2.2 Mice

STAT1+/+ and STAT1-/- mice on 129SV/EV background were purchased from
Taconic and maintained in our animal facility as per Institutional Animal Care Use
Committee (IACUC) regulation. STAT1-/- animals were generated in Dr. Robert
Schreiber’s lab [58]. Mice were originally genotyped using a modified HotSHOT genomic
DNA isolation protocol. Briefly, a tail snip was taken and incubated in 75µL of alkaline
buffer (25mM NaOH, 0.2mM EDTA) for 30 minutes at 95°C. Samples were then cooled
on ice and then 75µL of neutralization buffer (40mM Tris-HCl) was added to the samples,
vortexed and then centrifuged at 16,000xg for 5 minutes at room temperature. Then 100µL
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of the reaction (approximately 100ng/µL) was removed and stored at -20°C until used for
genotyping. To determine the genotype of the mice, the following PCR reaction was set
up: 2µL DNA, 20µM STAT1 F Primer, 20µM STAT1 R Primer, and 20µM NEO P3
Reverse Primer (see Table 2.1 for primers used), 12.5µL 2x GoTaq Hot Start Green
Master Mix (Promega, Madison, WI). The following PCR cycles were used to detect
STAT1: 1) 95°C for 4 minutes, 2) 95°C for 45 seconds, 60°C for 45 seconds, 72°C for 1
minute repeated 35 cycles 3) 72°C for 5 minutes. The PCR products were resolved on a
1% agarose/TBE gel with EtBr (ethidium bromide) to visualize the bands for STAT1 KO at
440bp and STAT1 WT (endogenous band) at 320bp. All STAT1+/+ and STAT1-/- mice
used during this study are indicated within the figure legends.
STAT2+/+, STAT2-/-, IFNAR+/+ and IFNAR-/- mice on 129SV/EV background
were a kind gift from Dr. Michael David at UCSD. Animals were maintained in their animal
facility as per IACUC regulation. STAT2-/- animals were generated in Dr. Schindler’s lab
[60]. The genotype of the animals was confirmed using western blot analysis, which is
described later within this chapter. IFNAR-/- mice were generated in Dr. Aguet’s lab in
1994 [149].
STAT2+/+ and STAT2-/- mice on C57BL6/J background were a gift from Dr. Anna
Gamero at Temple University. Animals were maintained in their animal facility as per
IACUC regulation. Mice were backcrossed onto the C57BL6/J background at Temple
University.
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Primer
Sequence
Stat1 Forward
5ʼ-CTACCAGAGTATCTGCCTAGAC-3ʼ
Stat1 Reverse
5ʼ-CCTCTCAACCTTCCTGACACC-3ʼ
NEOP3R
5ʼ-ATTCGCAGGGCATCGCCTTCTATCGC-3ʼ
Table 2.1 Primers used for STAT1 genotyping
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2.3 Mice and Interferon Injections

Animals were injected with varying concentrations of interferon and liver and other
organs were harvested at different times depending on the experiment. Briefly, when
looking at transcriptional regulation STAT1+/+ and STAT1-/- mice were injected by tail
vein with IFNβ (200,000 units). Control animals were injected with 1xPBS. RNA, DNA or
proteins were harvested 8 hrs post injection. When looking at the translocation of tyrosine
701 phosphorylation of STAT1 into the mitochondria, the interaction of STAT1 and
STAT2 in the mitochondria after IFNβ stimulation, or the tyrosine 689 phosphorylation of
STAT2 in the mitochondria, animals were injected with 400,000U per mouse and tissues
were harvested 30 minutes post injections. STAT1+/+ and STAT1-/- mice were also
injected with IFNγ (10ng/mouse) by tail vein injections and tissues were harvested eight
hours post injection. Control mice were injected with 1xPBS by tail vein injection. RNA,
DNA and protein were extracted from tissues and analyzed further according to the given
protocols.

2.4 RNA Extraction and cDNA Synthesis

RNA was isolated from tissue samples using TRI reagent. Briefly, the tissue was
minced into small pieces and then 1mL of TRI Reagent (Molecular Research, Cincinnati,
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OH) was added. Samples were incubated on a shaker at 4°C for 2 hours. Then 250µL
cholorform was added to the TRI Reagent and the samples were vortexed for 30 seconds at
high speed, and then incubated at room temperature for 10 minutes. Samples were then
spun down at 13,200 RPM for 10 minutes at 4°C. The aqueous phase was taken and
500µL of isopropanol was added. Samples were vortexed and RNA was pelleted at 13,200
RPM for 15 minutes at 4°C. The supernatant was removed and the RNA was washed with
75% ethanol. The samples were then centrifuged at 13,200 RPM for 10 minutes at 4°C.
Supernatant was removed and RNA pellet was dried at 37°C. RNA was re-suspended in
the appropriate amount of DEPC H2 O depending upon pellet size and then incubated at
55°C for 10 minutes. Isolated RNAs were treated with DNase (Promega, Madison, WI) in
a 1:10 ratio with DNase and Buffer and incubated at 37°C for 30 minutes. The treatment
was stopped by using Stop Buffer in a 1:10 ratio to total volume and incubated at 65°C for
10 minutes. RNA concentration was then determined and cDNA was synthesized from
2µg of RNA with the Tetro cDNA Synthesis Kit (Bioline, Taunton, MA). The synthesis
reaction includes 2µg RNA, 1µL Random Hexamer Primer Mix, 10mM dNTPs mix which
is preheated at 95°C for 1 minute then cooled to 4°C. Then the 5x RT Buffer, 200U
Reverse Transcriptase, 10U RNase Inhibitors, and DEPC H2O was added for a total
volume of 20µL and the PCR was set as follows: 42°C for 50 minutes, 70°C for 15
minutes and then cooled to 4°C.
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2.5 Quantitative PCR

mRNA levels of nuclear and mitochondrial encoded were analyzed by Real-Time
PCR using SensiMix SYBR and Fluorescein Kit (Bioline, Taunton, MA) according to
manufacturer’s instruction. Briefly, the cDNA was diluted to 1:25 ratio and 5µL of the
cDNA was used as the template for the reaction. The reaction mixtures for internal controls
were prepared as followed: 12.5µL of SYBER Green mix, 1µL 5µM forward primer, 1µL
5µM reverse primer, 5µL cDNA, and 5.5µL of dH2 O. For any other gene the mixture
reaction is as followed: 12.5µL of SYBER Green, 2.5µL 5µM forward primer, 2.5µL 5µM
reverse primer, 5µL of cDNA, and 2.5µL dH2O.

All the samples were assayed in

duplicates and analyzed using a CFX96 Real-Time PCR Detection System (Bio-Rad,
Hercules, CA). All primers used can be found in Appendices A, B, and C.

2.6 Mitochondrial DNA Isolation:

Genomic DNA was extracted from 5-10mg of tissue from mice according to
manufacturer guidelines from the Puregene Core Kit A (Qiagen). Briefly, lysis buffer was
added to the tissue along with Proteinase K and incubated at 55°C overnight. The next day,
the samples were spun down to remove excess tissue that was not digested. Then RNase
was added to the samples and incubated at 37°C for 30 minutes. After that, proteins were
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precipitated out of the solution with protein precipitation buffer. Then isopropanol was
added to the solution to precipitate the DNA from the samples. The samples were spun
down at 13,2000 RPM for 5 minutes at room temperature to pellet DNA, then washed
with 75% ethanol and centrifuged again at 13,200 RPM for 3 minutes at room temperature.
The pellet was air dried at room temperature for 5 minutes and the pellet was re-suspended
in DNA hydration buffer and then incubated at 55°C for 10 minutes and mixed overnight at
room temperature to reach maximum re-suspension of the DNA. Once isolated, 25ng of
genomic DNA was used for real-time PCR to measure mitochondrial DNA using SensiMix
SYBR and Fluorescein kit (Bioline Taunton, MA) according to manufacturer’s instructions.
All samples were assayed in duplicate and analyzed using a CFX96 Real-Time PCR
Detection System (Bio-Rad, Hercules, CA). Mitochondrial encoded genes measured were
ND4, ND6, Cytb, Cox1, ATPase6 and Actin as an internal control. Primer sequences for
the mitochondrial encoded genes can be found in Appendix A and the primer sequences for
nuclear encoded genes can be found in Appendix B.

2.7 Mitochondria Isolation:

Livers were harvested from mice. Tissue was washed with ice cold 1x PBS then the
livers were minced and homogenized in 10mL MSM-EDTA buffer (220mM Mannitol,
70mM Sucrose, 5mM MOPS, 2mM EDTA) on ice. Homogenized tissue was then
centrifuged at 500xg for 10 minutes at 4°C to remove cell debris. The supernatant was
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taken into a fresh tube and centrifuged at 5000xg for 10 minutes (Thermo Fisher Sorvall RC
6+ with the SS-34 rotor) at 4°C to pellet mitochondria. Mitochondria were then resuspended in 5mL of ice cold MSM-EDTA and spun down at 5,000xg for 10 minutes at
4°C. Supernatant was then discarded and the mitochondria were re-suspended in 2.5mL of
MSM-EDTA buffer for the final wash then spun down at 5000xg for 10 minutes at 4°C.
The supernatant was removed and mitochondria were re-suspended in 250µL MSM buffer
with protease and phosphtase inhibitors (Roche, San Francisco, CA) and aliquoted in 50µL
volumes and stored at -80°C. The mitochondria isolation protocol was modified from
combination of differential and Prercoll gradient centriguation from Dr. Edward
Lesnefsky’s lab at Virginia Commonwealth University.

2.8 Mitochondria Protein

Livers were harvested from mice and the weight was measured in grams (g).
Mitochondria were isolated and protein was measured using the Lowry method [150].
Once the protein concentration was determined, the calculation of milligrams (mg) of
mitochondrial protein / gram of liver was determined.

2.9 Protein Isolation

Tissue (20-50mg) was harvested from mice and snap frozen. Samples were then thawed

52
and minced into small sections and then lysed with whole cell extraction buffer (20mM
HEPES pH 7.0, 300mM NaCl, 10mM KCl, 1mM MgCl2, 20% Glycerol, and 1% Triton
X-100) with protease and phosphotase inhibitors added freshly before each use
(COMPLETE (1:25) and Phospho-STOP (1:10) Roche). Samples were incubated on ice for
30 minutes and insoluble cell debris was pelleted at 13,200 RPM for 10 minutes at 4°C.
Protein concentration was measured using the Bradford protein assay (Bio-Rad, Hercules,
CA).

2.10 Immunoprecipitation:

For Immunoprecipitation from cytosolic fractions, 250µg of protein was diluted in
250µL modified RIPA buffer (50mM Tri-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1%
Triton-X100 with protease and phosphatase inhibitors). Samples were diluted with RIPA
buffer to a concentration of 1µg/µL of protein. Samples were immunoprecipitated with
antibodies (diluted 1:1000) overnight on a rotor at 40C and 15µL of protein G Sepharose
(GE LifeSciences, Pittsburgh, PA) was added. The samples were then spun down the next
day and the “after” immunoprecipitation sample was taken. The immunoprecipitates were
washed 3 times with 500µL 1xPBS and centrifuged at 8,000xg for 1 minute at 4°C. After
the last wash, the beads were re-suspended in 20µL of SDS loading buffer and incubated at
95°C for 5 minutes. The samples were then subjected to SDS-PAGE electrophoresis.
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Proteins were transferred to Immobilon membranes and probed with specific antibodies.
For Immunoprecipitations from the mitochondrial extracts 500µg of protein was used
instead of 250µg of protein for total cell extracts. Primary rabbit polyclonal IgG was used
to ensure specificity of immunoprecipitations.

2.11 Western Blotting

Equal amounts of protein were mixed with 2x loading buffer (2x Laemmli Sample
Buffer (Bio-Rad) containing 1mM B-mercaptoethanol). Proteins were denatured at 95°C
for 5 minutes and spun down at room temperature. Proteins were separated using SDSPAGE electrophoresis, and then transferred onto Immobilon-P polyvinyldifluoridine
membrane (Millipore, Billerica, MA) using a semi-dry transfer apparatus (Bio-Rad,
Hercules, CA). Membranes were then blocked for 1 hour at room temperature in 5% nonfat milk in TBS-TWEEN buffer (20nM Tris-HCl, pH 7.5, 500mM NaCl, and 0.05%
Tween-20). Blots were then incubated overnight at 4°C in primary antibody diluted in 5%
BSA in TBS-TWEEN Buffer. After incubation, primary antibody was removed and the
membranes are washed three times each with 10mL TBS-TWEEN buffer for 9 minutes
each. Blots were then incubated for 1 hour at room temperature with secondary antibody at
1:10,000 (mouse or rabbit) diluted in TBS-TWEEN. The blots were then washed again
three times with 10mL TBS-TWEEN for 9 minutes each and then developed using ECLPlus (Pierce Thermo Scientific, Rockford, IL).
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2.12 Protein Quantification

Relative amounts of immunoreactive bands observed with ECLwas quantified from
western blots using the program Image J. Western blots were scanned and saved as a .jpg
with a quality better than 600 dpi. All westerns that were quantified using densitometry
were done in at least triplicates.

2.13 Electron Microscopy

Liver tissues were harvested from mice and washed in 1 x PBS and fixed in 2%
paraformaldehyde-2% glutaraldedhyde in 0.1M cacodylate buffer. The tissue was then
stored at 4°C and processed by the Microscopy Core Facility at the Department of
Anatomy and Neurobiology (VCU Medical Center, Richmond, VA). The samples were
embedded onto the membrane and sectioned. The samples were analyzed using the Joel
JEM-1230 Transmission electron microscope in the Microscopy Core Facility at VCU. To
determine the number of mitochondria per field in the STAT1+/+ and STAT1-/- liver,
thirty images were taken at 6000x magnification for each sample. Mitochondria were then
counted in the field with mitochondria touching the right and bottom edge not included. An
average number of mitochondria from thirty fields were determined from samples of
STAT1-/- and STAT1+/+ livers. The same protocol was used when comparing the number
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of mitochondria per field when mice were injected with IFNβ.

2.14 Platelet isolation from mouse blood

Blood was taken by heart puncture from 3-5 STAT1+/+ or STAT1-/- mice. The
blood was pooled in a heparinized blood collection tube (BD, Franklin Lakes, NJ) and then
diluted in a 1:1 ratio with 1xPBS/Tyrode buffer (10mM HEPES, pH 7.4, 10mM glucose,
137mM NaCl, 12mM NaHCO3, 2.7mM KCl, 0.36mM NAH2PO4, 1mM MgCl2) with
25units per mL of heparin. Blood was centrifuged 3X at 180xg for 3 minutes, 1X at 180xg
for 5 minutes and a last centrifugation at 180xg for 10 minutes at room temperature being
sure that no brake is used to slow the centrifuge. After each spin, a small portion of the
upper phase of plasma was taken which contains platelets known as the platelet rich
plasma (PRP). Once the platelets were isolated, the number of platelets were counted using
VetScan HMII a product of Abaxis and then equal amounts of platelets were incubated on
a rotator at room temperature with IFNβ or 1xPBS for 6 hours. Then protein or RNA was
harvested and analyzed further by RT quantification or western blotting.

2.15 Metabolite Measurements

Blood was collected from STAT1+/+ and STAT1-/- mice via heart puncture and
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placed within a plasma separator tube with lithium heparin from BD (365958). Once the
blood was collected, samples were centrifuged at 13,200 RPM for 5 minutes at room
temperature to obtain serum. The serum was then stored at -80°C. Samples were given to
our collaborator Dr. William Krozun at VCU School of Allied Health Professions, Clincial
Laboratory Sciences Department, for processing.

2.16 Glycogen Measurement

Livers were harvested from STAT1+/+ and STAT1-/- mice that were either fed or starved
for twenty-four hours and had free access to water.

350-400mg of livers were

homogenized and assayed using the Glycogen Assay Kit (700480) from Cayman Chemical.

2.17 Dietary Studies on STAT1+/+ and STAT1-/- mice

Eight week old STAT1+/+ and STAT1-/- mice were given normal chow diet and mice were
weighed every seven days for thirty-one days. To measure food intake, the amount of food
was measured for the starting amount and then measured again after twenty four hours to
determine the amount of food consumed per cage then per mouse. To determine the weight
lost during starvation, STAT1+/+ and STAT1-/- mice were weighed then starved for
twenty-four hours and weighed again. Animals that were starved were placed in clean cages
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and allowed to have free access to water.

2.18 Tissue Histology

Liver tissues from fed or 24 hour fasted STAT1+/+ or STAT1-/- mice were taken and
fixed in 10% formalin and stored at 4°C. The tissues were sectioned and stained with
hematoxylin and eosin at the Pathology Research Service Facility (VCU Medical Center,
Richmond, VA).

2.19 Oil Red O Staining of Liver Tissue

Livers were harvested from STAT1+/+ and STAT1-/- mice under basal and 24 hour
fasting conditions. Once the livers were removed, they were rinsed in 1xPBS and then snap
frozen in liquid nitrogen. The samples were processed at the Tissue & Data Acquisition &
Analysis Core (TDAAC) Department of Pathology, Virginia Commonwealth University,
Richmond, VA. The samples were fixed in 4% formaldehyde for 10minutes while shaking
at room temperature. After that, the samples were washed (while shaking) three times for
10minutes each with 1xPBS. Then the samples were removed and the excess liquid was
removed and the samples were washed in 60% isopropanol for 30seconds. The excess
isopropanol was then removed and the samples were stained with Oil Red O (Sigma) for
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15minutes. Briefly, to prepare the Oil Red O, re-suspend 0.5g Oil Red O in 100mL
isopropanol then the next day dilute: 6mL saturated Oil Red O with 4mL H2O, then filter
the solution four times, ensuring that the Oil Red O is protected from light. After the
samples are stained for 5 minutes the samples are then washed again in 60% isopropanol
for 30seconds. Slides are washed again while shaking, three times for 10minutes each with
1xPBS. The slides are covered and allowed to dry overnight at room temperature. The
samples are then imaged with a microscope at 10x and 40x.

2.20 Statistical analysis

Results are presented as the mean ± SE. Statistical comparison was performed using
two-tailed Student’s t-test when comparing two groups. When comparing more than two
groups, a one way ANOVA with a Tukey’s test was performed using the statical program
JMP. When interpreting the data, p-values less than 0.05 are considered statistically
significant and annotated by *.
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Chapter III
Results
Within the last five years there have been several studies that have shown that Jaks
and STATs have novel roles that are independent of their classical roles within the immune
system. Although STAT1 has been shown to localize to the mitochondria [77], the role of
mitochondrial STAT1 (mito-STAT1) has yet to be defined.
3.1 STAT1 is located within the Mitochondria
Previous studies from our group and other groups have shown that STAT3
localizes to the mitochondria [78, 151]. Hence, we wanted to examine the role of STAT1
within the mitochondria. Livers were harvested from STAT1+/+ and STAT1-/- mice and
mitochondria were isolated using a combination of differential and Percoll gradient
centrifugation and analyzed for expression of STAT1 using immunoprecipitation and
western blot analysis. Whole cell extracts were isolated from the livers from STAT1+/+
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and STAT1-/- mice as controls. Our results in Figure 3.1A, show that a small pool of
STAT1 is located within the mitochondria (mito-STAT1). Because an unspecific band that
is the same size as STAT1 is seen in the mitochondrial fractions in the input STAT1-/lanes on the western blot, immunopreciptation was done to verify the specificity of mitoSTAT1. The western blot was also analyzed for tubulin as a loading control and a cytosolic
marker. Porin was used as a mitochondrial marker. Histone 2B was used as a nuclear
marker. Mitochondria were not contaminated with the cytosolic or nuclear fraction since
both tubulin and histone 2B were not detected within the mitochondrial samples. An
immunoprecipitation was done with a nonspecific rabbit IgG antibody to validate the
specificity of the band seen in the STAT1+/+ liver mitochondria IP. Therefore the STAT1
seen in the mitochondrial samples is due to its presence in the mitochondria and not
cytosolic or nuclear contamination.

3.2 STAT1 null livers have increased levels of mitochondrial encoded mRNAs

The classical role of STAT1 is as a nuclear transcription factor. Since the
publications of the Lewis and Rubin groups in the early 1990s showed that interferon beta
(IFNβ) decreased mitochondria transcription, we wanted to determine whether mitoSTAT1 was acting as a transcription factor within the mitochondria [122-124]. Livers were
isolated from STAT1+/+ and STAT1-/- mice and RNA was isolated using TRIZOL. cDNA
was created from the RNA samples and analyzed using quantitative Real Time PCR
(qRTPCR) (primers are listed in appendix A and B). Table 3.1 is the summary of the
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results showing that STAT1-/- liver samples have increased levels of mitochondrial
encoded mRNAs compared to STAT1+/+ livers. This suggests that STAT1 is acting as a
negative regulator of mitochondrial transcription. One interesting finding within the
mitochondrial encoded mRNA levels is that ND6, which trends to be elevated, is not
significantly different between STAT1+/+ and STAT1-/- samples. ND6 is the only mRNA
that is encoded on the light strand of the mitochondrial genome which suggests that the
transcription of the heavy and light strand of the mitochondrial genome may be regulated
differently.
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Figure 3.1 STAT1 is located within the mitochondria. Whole Cell Extract (WCE) and
mitochondria were isolated from livers of STAT1+/+ and STAT1-/- mice. Samples (250µg
of WCE and 500µg of mitochondria ), were immunoprecipitated with STAT1 antibody or
IgG as a control and separated out on SDS-PAGE. (A) STAT1 or (B) IgG were probed for
STAT1 as well as Tubulin (cytosolic), porin (mitochondria), and Histone 2B (nuclear).
One representative blot out of four independent experiments is shown.
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Table 3.1 STAT1-/- livers have increased levels of mitochondrial encoded mRNAs.
Total RNA was isolated from STAT1+/+ and STAT1-/- livers and analyzed for expression
of mitochondiral gene expression using qRT-PCR. Expression levels of tubulin mRNA
were used as an internal control. The values represent mean fold increase ± SE for n = 10
female 6-8 week old 129 SvEv mice per group, * p < 0.05.
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3.3 STAT1 null livers have increased levels of nuclear components of the ETC.

Since STAT1-/- livers have increased levels of mitochondrial encoded mRNAs,
which are all components of the electron transport chain, we wanted to determine if the
transcriptional regulation of nuclear components of the electron transport chain was
STAT1 dependent. RNA was isolated from STAT1+/+ and STAT1-/- livers and analyzed
using qRTPCR. As seen in Table 3.2, STAT1-/- livers have increased levels of nuclear
encoded components of the electron transport chain when compared to STAT1+/+ livers.
This would suggest that STAT1 has the ability to coordinate regulation of both
mitochondrial and nuclear transcription of the electron transport chain components.
However, the regulation of all nuclear encoded mitochondrial RNAs are not STAT1
dependent, which suggests the specificity for this transcriptional regulation is complex,
Table 3.3.
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Table 3.2 STAT1-/- livers have increased levels of nuclear encoded ETC components.
Total RNA was isolated from STAT1+/+ and STAT1-/- livers and analyzed for expression
of nuclear encoded ETC components using qRTPCR. Expression levels of tubulin mRNA
were used as an internal control to normalize the expression of nuclear ETC genes within
STAT1+/+ and STAT1-/- mice. The values represent mean fold increase ± SE for n = 10
female 6-8 week old 129 SvEv mice pre group, *p < 0.05.
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Table 3.3 STAT1 does not regulate all nuclear encoded RNAs that synthsize
mitochondrial proteins. Total RNA was isolated from STAT1+/+ and STAT1-/- livers
and analyzed for expression of nuclear encoded mitochondrial RNAs using qRTPCR.
Expression levels were normalized with tubulin mRNA. The values represent mean fold
increase ± SE for n = 10 female 6-8 week old 129 SvEv mice per group, *p < 0.05.
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3.4 IFNβ negatively regulates mitochondrial transcription

The Lewis group in the early 1990’s showed that interferon beta inhibits
mitochondrial transcription; however, at that time the Jak-STAT pathway had not yet been
discovered [122-124]. Therefore, we wanted to determine if the inhibition of mitochondrial
transcription by type one interferons was STAT1 dependent. STAT1+/+ and STAT1-/mice were injected with either vehicle (1x PBS) or 200,000U IFNβ. Eight hours later,
livers were harvested and RNA was isolated and analyzed using qRTPCR. As a positive
control to verify that the IFNβ was injected properly and working, the mRNA level of a
nuclear encoded early response gene for interferon beta with a known ISRE element was
also measured. As seen in Figure 3.2, interferon-stimulated gene 54 (ISG54) is induced in
the STAT1+/+ mice injected with IFNβ but is not elevated in the STAT1-/- mice injected
with IFNβ. It can be concluded that the response to IFNβ is attenuated in the STAT1-/mice. As had been seen in the Lewis papers [122-124], IFNβ did inhibit all mitochondrial
encoded mRNAs on the heavy strand (Table 3.4). However, ND6, which does not appear
to be regulated basally by STAT1, is not inhibited by IFNβ. Since there is a down
regulation of some mitochondrial-encoded mRNAs in STAT1-/- mice treated with IFNβ,
this suggests that the inhibition by IFNβ can be STAT1 dependent or STAT1 independent.
This data suggests that the actions of IFNβ involve at least two regulatory mechanisms.
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Figure 3.2 IFNβ induces nuclear early interferon response gene expression, ISG54.
RNA was isolated from livers from STAT1+/+ and STAT1-/- mice injected with either
vehicle (1x PBS) or 200,000U IFNβ and analyzed using qRTPCR. Samples were
normalized to tubulin mRNA. The values represent mean fold increase ± SE for n = 10
female 6-8 week old 129 SvEv mice per group, *p < 0.05.
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Table 3.4 IFNβ inhibits mitochondrial encoded mRNAs. Eight hours post injection total
RNA was isolated from livers from STAT1+/+ and STAT1-/- mice injected with either 1x
PBS or 200,000U IFNβ. Samples were analyzed with qRTPCR and tubulin mRNA levels
were used as the internal control. The values represent mean fold increase ± SE for n = 10
female 6-8 week old female 129SvEv mice per group, *p < 0.05 to STAT1+/+. # p < 0.05
to STAT1-/-.
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3.5 IFNβ inhibits nuclear encoded components of the ETC

Many publications have shown that there is coordinate regulation of transcription
between the mitochondria and nucleus [129]. Since we found elevated mRNA levels of
nuclear components of the ETC in STAT1-/- livers, we wanted to determine if there is
inhibition of their expression upon exposure to IFNβ. RNA was harvested from livers of
animals that were injected with either 1x PBS or 200,000U IFNβ, (8 hrs post injection) and
analyzed using qRTPCR. As seen in Table 3.5, there appears to be decreased expression of
nuclear encoded components of the ETC in the STAT1+/+ mice upon IFNβ treatment;
however, this inhibition is not seen in the STAT1-/- IFNβ treated livers. This suggests that
STAT1 plays a role in negatively regulating the nuclear components of the ETC upon
IFNβ activation, which is lost in the absence of STAT1. This is an interesting result
because it could possibly suggest that STAT1 has a role in the cross talk between the
mitochondria and nucleus to co-regulate gene expression of the electron transport chain.
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Table 3.5 IFNβ inhibits nuclear encoded components of the ETC. Total RNA was
isolated eight hours post injection with either 1x PBS or 200,000U IFNβ from livers from
STAT1+/+ and STAT1-/-. Samples were analyzed with qRTPCR and normalized to the
internal control tubulin mRNA levels. The values represent mean fold increase ± SE for n
= 10 female 6-8 week old female 129 SvEv mice per group, *p < 0.05 compared to wildtype STAT1.
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3.6 Tyrosine 701 phosphorylation of STAT1 is needed to inhibit mitochondrial
transcription

It is well accepted that STAT proteins have to be tyrosine phosphorylated to be
activated and act as a transcription factor. STAT1 is no different in this manner, because it
has the conserved tyrosine at position 701. It has also been published that Serine 727
needs to be phosphorylated to reach maximal efficiency as a transcription factor in the
nucleus. Therefore, we wanted to determine if the tyrosine or the serine residues needed to
be phosphorylated to inhibit transcription within the mitochondria. Phospho-null mutant
STAT1 constructs were generated for either Serine727 mutated to alanine (S-A) or
Tyrosine701 mutated to phenylalanine (Y-F), and were stably expressed in a STAT1 null
cell line. Amounts of mitochondrial encoded mRNA were measured using qRTPCR.
Inhibition of mitochondrial gene expression was lost when tyrosine 701 but not Serine727
was mutated (data not shown). This suggests that tyrosine 701 but not serine 727 in
STAT1 is important to regulate mitochondria gene expression. To confirm these results, an
in vitro transcription assay was performed. Using all components needed for mitochondrial
transcription, plus the addition of either recombinant STAT1 or phospho-701 STAT1, to
determine if transcription was inhibited in either case. As seen in Figure 3.3A, with
increasing amounts of recombinant STAT1 or phospho-701 STAT1, mitochondrial
transcription was inhibited on the heavy strand and to a lesser degree, the light strand. This
data for transcriptional inhibition of the heavy and light strands has been quantified in
Figure 3.3B. To determine if tyrosine phosphorylated of STAT1 is located within the

73
mitochondria after wild-type mice were injected with IFNβ, livers were harvested and
mitochondria were isolated after thirty minutes and analyzed using immunoprecipitation
and western blot. This time point was chosen based on a time course that was done to show
maximal activation of phoso-701 STAT1 within a whole cell extract (data not shown). It
can be concluded from Figure 3.4A that upon IFNβ treatment, a small amount of
phosphorylated STAT1 translocates to the mitochondria. As seen in Figure 3.4B, the
bands seen in the mitochondria are specific for Phoso-701 STAT1 because there are no
bands seen when an unspecific antibody, IgG, was used for the immunoprecipitation.
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Figure 3.3 Mitochondria transcription is inhibited by P-STAT1 in vitro. Mitochondrial
transcription was measured in vitro with the addition of mitochondrial transcription
components: POLRMT (16nM), h-mtTFB2 (16nM), and LSP3 (3.4nM). (A) Dose
repsponse of HSP1 and LSP transcription to increasing amounts of either STAT1 or PSTAT1. (B) Quantification of transcription inhibition by STAT1 or P-STAT1 relative to
control reaction. Values represent 3 independent experiments. These experiments were
done by our collaborator at Yale University, Gerald Shadel.
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Figure 3.4 mito-STAT1 is tyrosine phosphorylated after IFNβ stimulation. Whole Cell
Extract (WCE) and mitochondria were isolated from livers of STAT1+/+ and STAT1-/mice injected with either 1xPBS or 400,000U IFNβ for 30 minutes. 250µg WCE and
500µg mitochondria were Immunoprecipitated with either (A) STAT1 or (B) IgG protein,
for unpsecific binding, separated out on SDS-PAGE and probed for P-STAT1, tubulin
(cytosolic), porin (mitochondria) and Histone 2B (nuclear). One representative blot out of
four independent experiments is shown.
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3.7 IFNβ inhibits mitochondria encoded mRNA expression in platelets.

To rule out the possibility of STAT1 activating a nuclear protein that translocates to
the mitochondria to inhibit transcription, we stimulated platelets with IFNβ. Platelets are
ideal for this experiment because they are nuclei free cells. Blood was pooled from 3-5
mice of STAT1+/+ and STAT1-/- and platelet rich plasma (PRP) was isolated by
centrifugation. After collection of the PRP from both wild-type and STAT1-null mice,
samples were treated with either 1x PBS or 10,000U IFNβ for six hours. RNA was then
isolated and analyzed using qRTPCR. As seen in Figure 3.5, platelets isolated from
STAT1-/- mice have increased levels of mitochondrial encoded mRNAs when compared to
STAT1+/+ mice, confirming the results seen in the livers samples (Table 3.2). When the
wild-type control is compared to the wild-type treated with IFNβ, it can be seen that
mitochondrial RNAs are decreased. Similar to liver, ND6 was not inhibited in platelets
treated with IFNβ. Samples were tested for nuclear cell contamination, and it was clear that
the PRP was not contaminated with leuokocytes, white or red blood cells (data not shown).
The inhibition seen in the wild-type samples is not seen in the STAT1-/- PRP treated with
IFNβ, which would suggest that this negative regulation is STAT1 dependent but it is
independent of the nucleus. In conclusion, IFNβ stimulation that inhibits mitochondrial
transcription in a Stat1-mediated mechanism which does not require the nucleus.
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Figure 3.5 IFNβ inhibits mitochondrial transcription in platelets. Blood was pooled
from 3-5 mice per group of either STAT1+/+ or STAT1-/- mice. 1 billion platelets were
either treated with 1x PBS or 10,000U/mL IFNβ for 6 hours. Total RNA was then isolated
and analyzed using qRTPCR. Samples were normalized to tubulin mRNA levels. The
values represent mean fold increase ± SE for n = 4 independent experiements, * p < 0.05.
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3.8 IFNγ does not inhibit mitochondrial gene expression.

Upon binding of IFNβ to its cell surface receptor, Jaks activate mainly STAT1 and
STAT2 which can either form a STAT1:STAT2 heterodimer or a STAT1:STAT1
homodimer. To determine which dimer plays a role in inhibiting mitochondrial
transcription, mice were treated with type II interferon (IFNγ), which activates STAT1 but
not STAT2. RNA was isolated and analyzed using qRTPCR. To verify IFNγ was injected
and stimulating properly, we looked at IRF1, which is an early response gene induced by
IFNγ. As seen in Figure 3.6, animals injected with IFNγ showed a significant increase in
IRF1 when compared to the control animals. Mitochondrial encoded mRNAs were
elevated in the STAT1-/- animals when compared to STAT1+/+ animals as seen in
previous experiments and as shown in Table 3.6. There is no inhibition seen in the
mitochondrial encoded mRNAs in wild-type animals injected with IFNγ in comparison to
the wild-type control animals. Also, there is no inhibition in the STAT1-/- injected with
IFNγ when compared to the STAT1+/+ or the STAT1-/- controls. This data would suggest
that the inhibition seen in mitochondria RNA expression upon stimulation of IFNβ is due
to a STAT1:STAT2 heterodimers and not STAT1:STAT1 homodimers. It was also seen
that IFNγ did not inhibit the nuclear components of the electron transport chain in the
STAT1 wild-type livers (Table 3.7). This supports the conclusion that STAT1:STAT1
homodimers do not play a role in the coordinate regulation of transcription in the
mitochondria and nucleus upon stimulation with IFNβ.
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3.9 Basal levels of IFNβ maintains mitochondrial transcription

It has been reported that low basal levels of IFNβ in mice allow for constant
activation of the Jak-STAT pathway; however, the physiological role of this low level of
IFNβ is not fully understood. To determine if basal levels of IFNβ are needed to maintain
mitochondrial transcription, we wanted to look at other components of this pathway. By
looking at either the IFNAR-/- mice, which is the receptor that IFNβ binds to or the
STAT2-/- mice, we were able to attenuate IFNβ signaling in the presence of STAT1.
Livers were harvested from IFNAR+/+ and IFNAR-/- animals, RNA was isolated and
analyzed using qRTPCR. As seen in Figure 3.7, mitochondrial encoded mRNAs are
elevated in the IFNAR-/-, as seen in the STAT1-/- livers. We also see that STAT2-/animals have increased levels of mitochondrial encoded transcription compared to wildtype animals, Figure 3.8. This would suggest that regulation of mitochondrial transcription
basally needs a small amount of IFNβ to activate the Jak-STAT pathway in order to keep
mitochondrial mRNA levels tightly controlled. Loss of any of the components of the
pathway, which attenuates the IFNβ signal, disrupts the ability of a cell to negatively
regulate mitochondrial transcription and leads to elevated mitochondrial mRNA levels.
However, it appears that the nuclear components of the ETC are regulated in a
STAT1 dependent manner that is independent of INAR or STAT2. As seen in Table 3.8
and Table 3.9, nuclear components of the ETC are not elevated in the IFNAR-/- or
STAT2-/- mice when compared to wild-type, which is contrary to what was seen in the
STAT1-/- livers (Table 3.2). These results suggest that under basal conditions, low levels
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of IFNβ maintain mitochondrial transcription, but there is an IFNβ independent pathway
that STAT1 is involved in that helps regulate nuclear encoded components of the ETC.

3.10 STAT1 and STAT2 co-localize in the mitochondria

To verify that STAT1 and STAT2 are regulating mitochondrial gene expression,
we wanted to show the expression of both STAT1 and STAT2 within the mitochondria.
Livers were harvested from wild type animals thirty minutes post injection with either 1x
PBS or 400,000U IFNβ. Mitochondria were isolated and analyzed by immunoprecipitation
and western blot analysis. As seen in Figure 3.9, STAT1 and STAT2 are seen to colocalize in the mitochondria under both basal conditions and IFNβ stimulation using
immunoprecipitation and western blot analysis. This would suggest that a STAT1:STAT2
heterodimer is located within the mitochondria to tightly control basal transcription and if
either STAT1 or STAT2 are not present this regulation is attenuated.
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Figure 3.6 IRF1 is activated upon IFNγ stimulation. RNA was isolated from livers of
STAT1+/+ and STAT1-/- mice injected with either vehicle (1xPBS) or 10ng per mouse for
8 hours. Samples were analyzed using qRTPCR and normalized to Tubulin mRNA levels.
The values represent mean fold increase ± SE for n = 5 female 6-8 week old 129 SvEv
mice per group, * p < 0.05.
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Table 3.6 IFNγ does not inhibit mitochondrial gene expression. Total RNA was
isolated from livers from STAT1+/+ and STAT1-/- mice either injected with 1x PBS or
10ng IFNγ. Samples were analyzed by qRTPCR and normalized to Tubulin mRNA levels.
The values represent mean fold increase ± SE for n = 5 female 6-8 week old 129 SvEv
mice per group, * p < 0.05 compared to STAT1+/+/ # p < 0.05 to STAT1-/-.
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Table 3.7 IFNγ does not inhibit transcription of nuclear components of the ETC.
Total RNA was isolated from livers from STAT1+/+ and STAT1-/- mice either injected
with 1x PBS or 10ng IFNγ. Samples were analyzed by qRTPCR and normalized to
Tubulin mRNA levels. The values represent mean fold increase ± SE for n = 5 female 6-8
week old 129 SvEv mice per group, * p < 0.05 to STAT1+/+. # p < 0.05 to STAT1-/-.
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Figure 3.7 IFNAR-/- livers have increased levels of mitochondrial encoded mRNAs.
Total RNA was isolated from livers from IFNAR+/+ and IFNAR-/- mice. Samples were
analyzed using qRTPCR and normalized using Tubulin mRNA levels. The values
represent mean fold increase ± SE for n = 6 female 6-8 week old 129 SvEv mice per group,
* p < 0.05.

85

Figure 3.8 STAT2 negatively regulates mitochondrial encoded gene expression. Total
RNA was isolated from livers from STAT2+/+ and STAT2-/- mice. Samples were
analyzed using qRTPCR for mitochondrial encoded mRNA levels and were normalized to
Tubulin mRNA levels. The values represent mean fold increase ± SE for n = 6 female 6-8
week old 129 WvEv mice per group * p < 0.05.
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Table 3.8 IFNAR-/- mice do not have elevated levels of nuclear encoded ETC
components. Total RNA was isolated from IFNAR+/+ and IFNAR-/- livers and were
analyzed using qRTPCR. Samples were normalized to the internal control Tubulin mRNA.
The values represent mean fold increase ± SE for n = 6 female 6-8 week old 129 SvEv
mice per group, * p < 0.05.
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Table 3.9 STAT2 does not play a role in negatively regulating nuclear components of
the ETC. Total RNA was isolated from the livers of STAT2+/+ and STAT2-/- mice.
Samples were analyzed using qRTPCR and normalized to Tubulin mRNA levels. The
values represent mean fold increase ± SE for n = 6 female week old 129 SvEv mice per
group, * p < 0.05.
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Figure 3.9 STAT1 and STAT2 co-localize within the mitochondria under
basal conditions. Whole Cell Extract (WCE) and mitochondria were isolated from
STAT1+/+ mice injected with either 1x PBS or 400,000U IFNβ for 30 minutes.
250μg WCE and 500μg mitochondria were immunoprecipitated with either (A)
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STAT2 or (B) IgG, for unspecific binding and probed with STAT1, Tubulin
(cytosolic) and Porin (Mitochondrial). This blot is a representative of 4 independent
experiments. 6-8 week old female 129 SvEv mice were used.
3.11 STAT1 regulates mitochondrial biogenesis

To rule out the possibility that the effect of increased mitochondrial mRNAs levels
in the STAT1-/-, IFNAR-/- and STAT2-/- livers is not due to increased mitochondrial
DNA or mitochondria copy number, we wanted to next investigate mitochondrial
biogenesis. PGC1α is the master regulator of mitochondrial biogenesis; therefore, we first
measured PGC1α within the STAT1-/-, IFNAR-/- and STAT2-/- livers. Surprisingly, we
see that STAT1-/- livers have increased levels of PGC1α when compared to wild-type.
However, neither IFNAR-/- or STAT2-/- livers show this increase, which can be seen in
Figure 3.10 (A-C). After determining that the levels of PGC1α were elevated within the
STAT1-/- livers, we wanted to look at the amount of mitochondrial DNA within the
STAT1-/- mice. Livers were harvested from STAT1+/+ and STAT1-/- mice and genomic
DNA was isolated and analyzed using qRTPCR. As seen in Figure 3.11, STAT1-/- livers
have increased levels of mitochondrial DNA (mito-DNA) in comparison to STAT1+/+
livers when normalized to nuclear DNA. IFNAR-/- and STAT2-/- mice did not have
increased mito-DNA compared to nuclear DNA (Table 3.10 and Table 3.11). This
suggests that STAT1-/- livers have increased mitochondrial DNA. To determine if this is
due to increased DNA copy number or increased number of mitochondria within the liver
of STAT1-/- mice, we looked at the number of mitochondria. To investigate this, images
were taken of the livers with the electron-microscope and the mitochondria were visually
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counted per field to determine if STAT1 knockout mice had more mitochondria. A
representative of the images counted can be seen in Figure 3.12. As seen in Figure 3.13,
the number of mitochondria is increased within the STAT1-/- livers compared to
STAT1+/+ livers. This would suggest that the increased amount of mito-DNA seen in the
STAT1-/- livers is due to the increased number of mitochondria and not increased copy
number of mito-DNA per mitochondria. To further prove that STAT1-/- livers have an
increased number of mitochondria, we measured the amount of mitochondria protein per
gram of liver. Figure 3.14A shows that STAT1-/- livers have increased mitochondrial
protein in comparison to STAT1+/+ livers, which is not seen in the IFNAR-/- (Figure
3.14B), or in the STAT2-/- livers (Figure 3.14C). By western blot, it can be seen that
STAT1-/- mice have increased levels of Cox1 protein, which is a mitochondrial encoded
protein, Figure 3.15. This data taken together, suggest that STAT1 plays a role in
regulating mitochondrial biogenesis, which is independent of its activation by the classical
pathway of IFNβ. It appears that STAT1 is regulating the mitochondrial biogenesis
through the transcriptional regulation of PGC1α. However to fully understand this
mechanism, more studies are needed.
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Figure 3.10 STAT1-/- livers have increased levels of PGC1α. (A) Total RNA was
isolated from STAT1+/+ and STAT1-/- mouse livers and PGC1α mRNA levels were
measured using qRTPCR and normalized to Tubulin mRNA levels. n = 5 6-8 week old
female 129 SvEv mice. (B) Total RNA was isolated from IFNAR+/+ and IFNAR-/- mice
and PGC1α mRNA levels were measured using qRTPCR and normalized to Tubulin
mRNA. n = 6 6-8 week old male 129 SvEv mice. (C) Total RNA was isolated from
STAT2+/+ and STAT2-/- mouse livers and PGC1α mRNA levels were measured using
qRTPCR and normalized to Tubulin. n = 6 6-8 week old female 129 SvEv mice.
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Figure 3.11 STAT1-/- have increased mitochondrial DNA. Total genomic DNA was
isolated from livers of STAT1+/+ and STAT1-/- mice. Samples were analyzed for the
expression of mitochondria DNA (ND4, ND6, Cytb, Cox1 and ATPase6) using qRTPCR
and all samples were normalized with Actin mRNA levels. The values represent mean fold
increase ± SE for n = 5 male 6-8 week old 129 SvEv mice.
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Table 3.10 IFNAR-/- mice do not have increased mitochondrial DNA. Total genomic
DNA was isolated from livers from IFNAR+/+ and IFNAR-/- mice. Samples were
analyzed for the expression of mitochondria DNA (ND4, ND6, Cytb, Cox1 and ATPase6)
using qRTPCR and all samples were normalized to Actin mRNA levels. The values
represent mean fold increase ± SE for n = 6 male 6-8 week old 129 SvEv mice.
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Table 3.11 STAT2-/- mice do not have increased mitochondrial DNA. Total genomic
DNA was isolated from livers from IFNAR+/+ and IFNAR-/- mice. Samples were
analyzed for the expression of mitochondria DNA (ND4, ND6, Cytb, Cox1 and ATPase6)
using qRTPCR and all samples were normalized with Actin mRNA levels. The values
represent mean fold increase ± SE for n = 5 male 6-8 week old c57 Black 6 mice.
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Figure 3.12 STAT1-/- mice have increased number of mitochondria in the liver.
Images of STAT1+/+ and STAT1-/- livers were taken with the TEM JOEL at 6000x
magnification. Mitochondria are shown by the arrows. These images are a representation
of n = 4 independent experiments where 6-8 week old male 129 SvEv mice were used.
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Figure 3.13 STAT1-/- mice have increased number of mitochondria. Images of
STAT1+/+ and STAT1-/- livers have taken with TEM JOEL at 6000x magnification.
Thirty random images were taken for 3 independent experiments. Mitochondria were
counted per field and averaged. The values represent the mean ± SE, * p < 0.05.

97

Figure 3.14 STAT1-/- mice have increased mitochondrial protein within the liver.
Livers were weighed and mitochondria were isolated. Protein levels were measured using
the Lowry method and milligram of mitochondrial protein per gram of liver was
calculated. (A) STAT1+/+ and STAT1-/- mice, n = 5 male 6-8 week old 129 SvEv mice.
(B) IFNAR+/+ and IFNAR-/- mice, n = 6 male 6-8 week old 129 SvEv mice. (C)
STAT2+/+ and STAT2-/- mice, n = 6 male 6-8 week old c57 Black 6 mice. Values
represent the mean ± SE, * p < 0.05.
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Figure 3.15 STAT1-/- mice have increased levels of mitochondrial protein.
Mitochondria were isolated from livers of STAT1+/+ and STAT1-/- mice. Samples were
separated by SDS-PAGE and probed for Cox1 a mitochondrial encoded protein and porin,
as an internal control. This blot is a representation of 4 independent experiments, where 68 week old female 129 SvEv mice were used.
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3.12 STAT1-/- livers do not have increased mitochondrial biogenesis during
starvation
One simple way of increasing mitochondria biogenesis is through starvation.
During starvation, within the liver, PGC1α levels are increased which in turn will increase
mitochondrial biogenesis [152]. We wanted to determine if under stress was possible to
further increase the number of mitochondria within the livers of STAT1-/- mice. Wild-type
and STAT1-null mice were either fed or starved for a twenty-four hour period with free
access to water. The mice were then sacrificed and livers were harvested. RNA was
isolated and analyzed using qRTPCR. As can be seen in Figure 3.16, PGC1α is increased
in the wild-type livers under starved conditions, but starvation had no effect on STAT1-/livers. However, the basal levels of PGC1α in the STAT1-/- livers are elevated compared
to wild-type controls. This would suggest that under stressful conditions, the STAT1-/animals do not have the ability to further increase PGC1α or mitochondrial biogenesis. As
expected, the livers of the STAT1-/- livers under starved conditions did not have increased
mitochondrial encoded mRNAs when compared to the STAT1-/- fed mice. However the
STAT1+/+ livers under starved conditions had both increased mitochondria encoded
mRNA levels and increased mitochondrial DNA (Figure 3.17 and Figure 3.18). When
measuring the mitochondrial protein in comparison to the size of the liver in the wild-type
and STAT1 null mice (Figure 3.19), the STAT1+/+ starved mice had an increase in
mitochondrial protein levels in comparison to the STAT1+/+ control mice. There were no
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changes in the STAT1-/- mice that had been either fed or starved. After starving a wildtype animal, the level of total STAT1 protein decreases which may be part of a mechanism
to increase mitochondrial biogenesis (Figure 3.20A). Not surprisingly, since STAT2 does
not play a role within mitochondrial biogenesis, shows that STAT2 levels are unchanged in
this case (Figure 3.20B). The conclusion of these results is that the STAT1-/- mice do not
have the ability to increase their mitochondrial biogenesis under the stress of starvation
like the STAT1+/+ mice. It is likely STAT1 is playing a role in the regulation of
mitochondrial biogenesis.

101

Figure 3.16 STAT1-/- mice do not have increased PGC1α under starvation. Total
RNA was isolated from STAT1+/+ and STAT1-/- mice who were either fed or starved for
a twenty four hour period. Animals had free access to water. PGC1α levels were measured
using qRTPCR and samples were normalized to Tubulin mRNA levels. The values
represent mean fold increase ± SE for n = 5 male 6-8 week old 129 SvEv mice per group,
*p < 0.05.
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Figure 3.17 STAT1-/- mice do not have increase mitochondrial mRNA levels under
starvation. Total RNA was isolated from STAT1+/+ and STAT1-/- mice that were either
fed or starved with free access to water. Mitochondrial encoded mRNA expression levels
were measured using qRTPCR and Tubulin mRNA levels were used as the internal
control. The values represent mean fold increase ± SE for n = 5 male 6-8 week old 129
SvEv mice per group, * p < 0.05.
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Figure 3.18 STAT1-/- livers do not have increased mito-DNA during starvation. Total
genomic DNA was isolated from livers from STAT1+/+ and STAT1-/- mice, which were
either fed or starved and had free access to water during a twenty-four hour period.
Samples were analyzed for the expression of mitochondria DNA (ND4, ND6, Cytb, Cox1
and ATPase6) using qRTPCR and all samples were normalized with Actin mRNA levels.
The values represent mean fold increase ± SE for n = 5 male 6-8 week old 129 SvEv mice,
* p < 0.05.
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Figure 3.19 STAT1-/- livers do not have increased mitochondrial protein during
starvation. Mitochondria were isolated from STAT1+/+ and STAT1-/- mice which were
either fed or starved during a twenty-four hour period and had free access to water. The
weight of the livers was taken in grams (g) and the mitochondrial protein was measured
using the Lowry method. Then the milligrams (mg) of mitochondrial protein per g of liver
was calculated. The values represent mean fold increase ± SE for n = 5 male 6-8 week old
129 SvEv mice, * p < 0.05.
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Figure 3.20 STAT1 protein levels are decreased during starvation. Whole Cell Extract
(WCE) was isolated from STAT1+/+ mice and separated on SDS-PAGE and probed for
STAT1, STAT2 and Tubulin as a loading marker. Densitometry was measured using
ImageJ with 3 independent experiments. The values represent mean fold increase ± SE for
n = 3 male 6-8 week old 129 SvEv mice, * p < 0.05.
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3.13 STAT1-/- mice have dysregulation of metabolic enzymes

STAT1 appears to play a role in the regulation of mitochondrial biogenesis during
starvation. Many metabolic processes are affected during starvation and as such we were
curious if any of the pathways were altered in the STAT1-/- mice during starvation when
compared to the STAT1+/+ mice. Male STAT1+/+ and STAT1-/- mice were either fed or
starved for a twenty-four hour period where the animals had free access to water. The
livers were harvested and RNA was isolated and analyzed using qRTPCR. It can be seen in
Table 3.12 , that there are alterations in the gene expression of metabolic enzymes in basal
conditions in the STAT1-/- and the STAT1-/- starved animals. As seen from glucokinase
and LPK gene levels in the STAT1-/- ST samples compared to STAT1+/+ ST, this data
might suggest that the STAT1-/- mice have an inability to turn off glycolysis, which is
responsible for the break down of sugar during starvation (Table 3.12). This data also
suggests that STAT1-/- livers are less efficient at breaking down fatty acids when
compared to the STAT1+/+ livers (compare STAT1+/+ ST and STAT1-/- ST samples in
the following genes: LCAD, Cpt1b, Scd-1 and FAS). Taken together this data would
suggest that there are defects within the metabolic processes that turn off glycolysis and
turn on fatty acid break down within the liver of the STAT1-/- mice during starvation.
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Table 3.12 Dysregulation of Metabolic Enzymes in STAT1-/- livers during starvation.
Total RNA was isolated from livers of STAT1+/+ and STAT1-/- mice which were either
fed or starved during a twenty-four hour period which had free access to water. Samples
were measured with qRTPCR and normalized to Tubulin mRNA levels. The values
represent mean fold increase ± SE for n = 5 male 6-8 week old male 129 SvEv mice, * p <
0.05 compared to STAT1+/+. # p < 0.05 compared to STAT1-/-.
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3.14 STAT1-/- livers have less lipid droplets during starvation

Upon starvation, the body will first deplete the glycogen stores and then break
down fat stores. The adipose tissue is broken down into triglycerides and glycerol and
transported into the liver where it is further broken down to send glucose to the other
tissues; therefore, lipid droplets will increase within the liver during fasting to maintain
glucose homeostasis. Based upon the liver enzymes measured, the STAT1-/- starved mice
showed a defect in the break down of fatty acid synthesis which would suggest that they
either have an inability to break down the lipids within the liver or an inability to transport
lipids to the liver. To determine this, we took STAT1 wild-type and null mice and fed or
starved them for twenty-four hours. The livers were then harvested and samples were sent
for sectioning. The liver sections were then stained with H&E (to assess structure) or Oil
Red O (a lipophilic dye to assess lipid storage). As seen in Figure 3.21, the H&E shows
that there are no visible morphological defects within the STAT1+/+ and STAT1-/- livers;
however there are fewer lipid droplets seen in the STAT1-/- compared to the STAT1+/+
under starvation. This is also confirmed with Oil Red O staining of the livers in Figure
3.22. This data suggests that STAT1-/- mice have an inability to translocate fat to the liver
during fasting conditions.
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Figure 3.21 H&E staining in STAT1+/+ and STAT1-/- livers.
hematoxylin-eosin staining. 129 SvEv n = 5 mice per group.

Representative
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Figure 3.22 Oil Red O staining in the STAT1+/+ and STAT1-/- livers. Lives from
STAT1+/+ and STAT1-/- mice were sectioned and lipids were stained with Oil Red O.
Images are representative of 5 independent groups of male 6-8 week old 129 SvEv mice.
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3.15 STAT1-/- mice have an inability to break down fat

Upon starving the STAT1+/+ and the STAT1-/- mice, we observed that the
STAT1-/- mice did not lose their subcutaneous fat pads after a twenty-four hour starvation,
as seen in Figure 3.23, This supports the data collected from the metabolic enzyme mRNA
levels in the livers from the STAT1-/- and STAT1+/+ either fed or starved. The STAT1+/+
and STAT1-/- mice showed no significant difference in weight before the starvation and
lost the same amount of weight during starvation, as seen in Figure 3.24A and C. These
animals also had the same amount of food intake Figure 3.24B, suggesting that the
STAT1-/- mice are using an energy source other than fat to produce energy during
starvation.
To further confirm that the STAT1-/- mice have a defect in their white adipose
tissue during starvation, we examined the break down of fatty acids within the adipose
tissue after starvation. To do this, STAT1+/+ and STAT1-/- mice were either fed or starved
for a twenty-four hour period, then the subcutaneous fat was isolated and protein was
extracted and analyzed by western blot. Hormone Sensitive Lipase (HSL) levels were
measured in these samples, and as seen in Figure 3.25B, the STAT1-/- animals have a
defect in the ability to activate HSL upon starvation when compared to the STAT1+/+
mice. The STAT1-/- mice have increased basal phosphorylation of HSL compared to
STAT1+/+. Total levels of HSL are unaffected basally in the STAT1-/- and STAT1+/+
mice, and the total level of HSL is increased in both the STAT1+/+ ST and the STAT1-/ST samples (Figure 3.25A). Because the STAT1 null animals have a defect in their ability
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to activate HSL once starved, this would suggest that STAT1-/- mice are less efficient in
breaking down lipids during a stressful condition such as starvation. This would suggest
that the adipocytes do not have the ability to receive the signal to activate the HSL.
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Figure 3.23 Images of STAT1+/+ and STAT1-/- mice after starvation. STAT1+/+ and
STAT1-/- mice were starved for twenty-four hours. Arrows point to the subcutaneous fat
pads. The images shown are the representative of 5 independent groups of male 6-8 week
old 129 SvEv mice.
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Figure 3.24 Weight and food intake of STAT1+/+ and STAT1-/- mice. (A) The weight
of male STAT1+/+ and STAT1-/- mice was measured weekly starting at 8 weeks of age
and continued through 31 weeks. (B) Food intake was measured during a twenty-four hour
period weekly for male mice starting at 8 week old and continues through 31 weeks. (C)
The weight of mice was measured before and after a twenty-four hour period of starvation
and the calculation of weight lost was calculated. n = 5 male 6-8 week old 129 SvEv mice.
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Figure 3.25 STAT1-/- mice have defects in activating HSL in fat. Whole Cell Extract
was isolated from subcutaneous fat of STAT1+/+ and STAT1-/- mice either fed or starved
during a twenty-four hour period. Samples were separated on SDS-PAGE and probed for
(A) total HSL and (B) phosphorylated HSL and tubulin as an internal control.
Denistometry was used to measure the amount of either (A) HSL or (B) P-HSL using
ImageJ and were normalized to tubulin. The blots are representative of n = 5 male 6-8
week old 129 SvEv mice, * p < 0.05.
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3.16 Defects within Metabolite levels in STAT1-/- mice during starvation
Because the STAT1-/- mice have defects in activating the break down of adipose
tissue during starvation, they have to be producing energy from another source, which is
most likely from the break down of proteins. To verify this hypothesis, we examined
different metabolites in the serum of STAT1+/+ and STAT1-/- mice either during fed or
starved conditions. As seen in Figure 3.26, the STAT1+/+ and STAT1-/- mice do not have
any differences basally in any of the metabolites. However when comparing the STAT1+/+
and STAT1-/- under starved conditions, we found that the STAT1-/- mice have increased
levels of glucose compared to the STAT1+/+, which corresponds to the data seen in the
liver where glycolysis is not turned off (Figure 3.26C). Lactate levels are not decreased
within the STAT1-/- ST mice as would be expected within the STAT1+/+ ST mice, Figure
3.26D. To prove that the STAT1-/- mice do not have increased stores of glycogen or a
defect in using the glycogen stores upon starvation, we measured the levels of glycogen
within the liver in both fed and starved conditions in STAT1+/+ and STAT1-/- mice. As
seen in Figure 3.27, there are no significant changes of glycogen in the STAT1+/+ or
STAT1-/- mice either during feeding or starvation. This data would suggest that STAT1-/mice have a defect within pathways breaking down fat during fasting conditions.
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Figure 3.26 Metabolites within STAT1+/+ and STAT1-/- mice. Blood was taken from
STAT1+/+ and STAT1-/- mice and plasma was separated. (A) Cholestrol, (B)
Triglycerides, (C) Glucose, and (D) Lactate were measured. The values represent mean ±
SE for n = 5 male 6-8 week old 129 SvEv mice, * p < 0.05.
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Figure 3.27 Glycogen levels in livers from STAT1+/+ and STAT1-/- mice. Livers were
homogenized from STAT1+/+ and STAT1-/- mice, which were either fed or starved for a
twenty-four hour period with free access to water. Glycogen was measured using the
ELISA Assay kit. The values are mean ± SE for n = 5 male 6-8 week old 129 SvEv mice, p
< 0.05.

Chapter IV
Discussion
Mitochondria play a key role in energy metabolism, cell cycle regulation, oxygen
sensing and antiviral responses [153-155]. For mitochondria to exert its actions there has to
be coordinate regulation between the mitochondria and the nucleus. The understanding of
this crosstalk has not been fully elucidated. It is well known that the transcription factor,
STAT1, has the capacity to regulate antiviral mechanisms within the cell, while it also
contributes to cell growth control and energy regulation during transformation [83, 115,
117]. In this study, we provide evidence of a novel mechanism that basal activation of the
classical Jak-STAT pathway helps to maintain mitochondrial homeostasis and when this
pathway is disrupted the equilibrium is shifted. We also provide evidence that STAT1 is a
negative regulator of mitochondrial biogenesis and energy homeostasis during starvation.
Type I interferons (IFNβ) have been shown to be constitutively expressed at low
levels in mice that are not stressed. Under these conditions tyrosine phosphorylated STAT1
and STAT2 can form heterodimers and regulate a subset of genes [116]. In this study, we
show that STAT1 and STAT2, nuclear transcription factors, play a role in negatively
regulating mitochondrial transcription (Table 3.1 and Figure 3.8). The mechanism for this
119
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negative regulation is not fully understood. However, my results led us to hypothesize that
repression of mitochondrial transcription is mediated through the basal activation of the
Jak-STAT pathway by IFNβ. Mitochondrial encoded RNAs in the livers of the interferon
alpha receptor (IFNAR) knockout mice (Figure 3.7), are elevated in comparison to wildtype mice. The same is seen in the STAT1 and STAT2 knockout mice (Table 3.1 and
Figure 3.8). For IFNβ to signal from the cell surface IFNAR1 needs to be available to
receive the signal, which then allows docking sites for STAT1 and STAT2 to be tyrosine
phosphorylated by the Jaks. The activated STAT proteins will then form homo or
heterodimers. If any of these components are non-functional or deleted, then the IFNβ
signal is attenuated and there is no longer inhibition of mitochondrial gene expression.
Previous studies done with STAT1 and STAT2 knock out mice show that they have an
ablated type I interferon response and are unable to induce an immune response to bacteria
and viruses. It can also be seen that STAT1 is located within the mitochondria (Figure 3.1)
and co-localizes there with STAT2 (Figure 3.9) under basal conditions in control animals,
which supports the hypothesis that it is STAT1:STAT2 heterodimers that suppress
mitochondrial gene suppression and not STAT1:STAT1 homodimers. Surprisingly,
STAT1 and STAT2 interaction appears to decrease in the mitochondria after IFNβ
stimulation. It is possible that STAT1 and STAT2 are parts of a protein complex that
inhibits mitochondrial transcription basally but they are displaced after IFNβ signaling. It
has been reported that under high dosages of IFNβ the protein levels of STAT1 and
STAT2 are changed which leads to a change in gene expression, which could explain why
under basal conditions we see STAT1 and STAT2 co-localizing in the mitochondria, but
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after exogenous IFNβ this interactions decreases [156]. It is also possible that they will
bind to the mitochondrial DNA to inhibit transcription. At this time however, there is not a
known ISRE site within the regulatory D-Loop of the mitochondrial genome, but there is a
weak GAS element within the D-Loop (data not published, Larner lab). This could lead to
the possibility that a STAT1:STAT2 heterodimer that is independent of IRF9 could bind to
the GAS element [157]. It is also not fully understood how STAT1 and STAT2 translocate
to the mitochondria because neither have classical mitochondrial localization sequences.
The published papers of the early 1990s, suggested that type I interferons inhibit
mitochondria gene expression, which agrees with what we observe in the IFNAR null
animals.

Our results suggest that IFNβ inhibition has both a STAT1 dependent and

independent component (Table 3.4). The evidence provided from Table 3.4 shows that a
majority of the mitochondrial encoded mRNAs are negatively regulated in the STAT1-/mice upon stimulation with IFNβ, which points to a requirement for a STAT1 independent
factor in mediating this signaling event. This is interesting because it would suggest that
IFNβ is activating a second signaling cascade that is not through the Jak-STAT pathway to
negatively regulate mitochondrial gene expression in the absence of STAT1. This adds a
layer of complexity to the inhibition seen with IFNβ, which has yet to be explored. It will
be of interest to see if the same inhibition is seen on mitochondrial transcription in the
STAT2-/- and IFNAR-/- mice upon stimulation with IFNβ.
In line with the thinking that there must be parallel regulation between nuclear and
mitochondrial encoded genes for the mitochondria, we also see that STAT1 has the ability
to coordinately regulate the expression of nuclear encoded components of the ETC (Table
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3.2). When other nuclear encoded mitochondrial genes that were not apart of the ETC it
appears that most are not regulated by STAT1 (Table 3.3), suggesting another component
that regulates the transcription of their expression. What’s interesting though is that it
appears that STAT1 is performing this action independent of the classical Jak-STAT
pathway. Since the expression of the nuclear encoded ETC components are not upregulated within the IFNAR-/- (Table 3.8) or the STAT2-/- livers (Table 3.9). It would
suggest that STAT1’s regulation of these genes does not require the same upstream
signaling events as was seen for the control of the mitochondrial encoded mRNAs.
It was reported in earlier papers that the transcription on the light strand was not
inhibited by IFNβ, and we confirm that result in Table 3.4. Surprising, ND6 transcript
levels are not elevated basally within the STAT1-/- liver, although, ND6 expression level
is elevated within the IFNAR-/- (Figure 3.7) and STAT2-/- (Figure 3.8) mice. This
suggests a second mechanism for the transcriptional regulation of the light strand where an
additional signal is needed to inhibit transcription. Not surprising, we see that IFNβ also
inhibits the expression of the nuclear encoded components of the electron transport chain
in STAT1+/+, but not STAT1-/- livers (Table 3.5). It is possible that inhibition is seen
with exogenous IFNβ because it regulates a different subset of genes with the changes in
STAT1 protein levels seen with high dosage of IFNβ [156]. This would suggest that the
nuclear component of the inhibition mediated by IFNβ appears to be fully STAT1
dependent. However it will be interesting to look at the negative regulation in the STAT2
knock out mice upon stimulation of IFNβ. The inhibition seen appears to be type I
interferon specific because we do not see the same negative regulation on either the
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mitochondrial gene expression (Table 3.6) or nuclear ETC components (ETC) upon
injection with type II interferon (IFNγ) (Table 3.7). This is most likely due to the fact that
IFNγ mainly activates a STAT1:STAT1 homodimer which does not appear to mediate the
inhibition. From the data provided, mitochondrial inhibition is mediated through a
STAT1:STAT2 heterodimer which is formed under IFNβ activation. With IFNγ the
nuclear encoded ETC components are significantly reduced within the STAT1-/- mice,
which would suggest a negative regulation; however to fully understand this more studies
are needed.
It is well accepted that STAT1 has to be tyrosine phosphorylated to be activated
and that serine 727 (S727) is needed for maximal function within the nucleus. Because of
this, we wanted to determine if STAT1 is tyrosine or serine phosphorylated within the
mitochondria. Studies were done previously within the lab that showed that mutating
tyrosine 701 to phenylalanine (Y701F), but not serine 727 to alanine (S727A), prevented
this basal inhibition of mitochondrial encoded mRNAs. This would suggest that STAT1
needs to be tyrosine phosphorylated for transcriptional inhibition to occur within the
mitochondria. This is shown also by the in vitro transcription assays that were performed
(Figure 3.3) by our collaborator, Dr. Gerry Shadel, at Yale University. It is notable that
inhibition of transcription from the light strand promoter required much more P-STAT1
than the heavy strand. There have been reports published that show that U-STAT1 and PSTAT1 can transcriptionally regulate the same subset of genes depending on cell type [74],
which may be the reason we see that both U-STAT1 and P-STAT inhibiting mitochondrial
transcription. It can be seen that after wild-type mice were injected with IFNβ a fraction of
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the tyrosine phosphorylated STAT1 is located within the mitochondria (Figure 3.4). Under
basal conditions, it is most likely a small pool of mito-STAT1 is also phosphorylated
however the amount is not consistently detectable. The mechanism of how mito-STAT1 is
phosphorylated has yet to be determined. Moreover, it is unclear at this point if mitoSTAT1 has to be phosphorylated in order for it to translocate to the mitochondria, or if it
can be phosphorylated once there. These data all suggest that STAT1 needs to be tyrosine
phosphorylated to inhibit mitochondrial transcription, while it appears that Serine 727 is
not essential, because of the results showing mutating Serine 727 to alanine still leads to
inhibition of mitochondrial gene expression. It will be of interest to further study posttranslational modifications of STAT1 and the mechanism of STAT1’s ability to translocate
into the mitochondria.
It appears that the IFNβ mediated inhibition of mitochondrial transcription is
independent of the nucleus. Platelets are the ideal experimental tool to rule out the nuclei
within this pathway because they are a-nucleated cells. When platelets were isolated from
STAT1+/+ mice and stimulated with IFNβ, we see that there is still inhibition of
mitochondrial encoded genes (Figure 3.5). We also see that basal transcriptional
regulation of mitochondrial encoded mRNAs is independent of nuclei as well because as
seen in the liver STAT1-/- platelets have elevated mRNA levels (Figure 3.5). This data
would suggest that IFNβ inhibition is signaled from the cell surface to the cytoplasm to the
mitochondria, which again points to a novel mechanism at play here. One question that
remains to be addressed is what happens in a STAT2 null system.
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Mitochondrial biogenesis occurs when a cell needs to produce more energy. The
master regulator of mitochondrial biogenesis is PGC1α, and it’s transcription can be
regulated by STAT1 among other things. As seen in Figure 3.10A, PGC1α levels are
elevated within STAT1-/- livers when compared to wild-type livers, and this is not seen in
IFNAR-/- or STAT2-/- Figure 3.10 B and C. It will be of interest to determine protein
levels of PGC1α within the STAT1+/+ and STAT1-/- livers because PGC1α is regulated
mainly through post-translational modifications; however, this is currently not possible
because there is not an antibody available that recognizes murine PGC1α. Along with an
up-regulation of PGC1α, STAT1-/- livers have increased mitochondrial DNA (Figure
3.11), mitochondrial protein (Figure 3.14A and Figure 3.15), and number of
mitochondria (Figure 3.12 and Figure 3.13). Again this is not seen in the IFNAR (Table
3.10) and STAT2 (Table 3.2) knock out mice. One explanation for the elevated expression
of the nuclear components of the ETC within the STAT1-/- mice could be due to increased
mitochondrial biogenesis within the STAT1-/- mice that is driving the increase we see in
the nuclear encoded genes (Table 3.2). This data would suggest that STAT1 has the ability
to regulate mitochondrial biogenesis under basal conditions and that it is independent of
the classical Jak-STAT pathway. Investigations into this pathway could provide a better
understanding of how mitochondrial biogenesis regulation occurs and possibly lead to
targeted drug therapies for obesity or mitochondrial diseases.
To mimic what we see in the STAT1 null animals under basal conditions we sought
to find a physiological condition where mitochondrial biogenesis was increased.
Interestingly, the energy required during starvation to maintain glucose homeostasis within
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the liver requires an increase in mitochondrial biogenesis. Elevated levels of PGC1α
activate the increase in biogenesis. As seen in the wild-type mice, which were starved for
twenty-four hours, PGC1α is elevated compared to wild-type controls. However, an
increase in PGC1α is not observed in STAT1-/- livers during starvation (Figure 3.16).
This would suggest that a decrease in STAT1 is needed for the increase in PGC1α under a
stressful condition such as starvation for mitochondrial biogenesis to be increased. This
would suggest that STAT1 plays a dual role when regulating the mitochondria, which
occurs in an environmental dependent manner. To further investigate the role of STAT1 in
mitochondrial biogenesis during starvation, mitochondrial encoded mRNA (Figure 3.17),
mitochondrial DNA (Figure 3.18) and mitochondrial protein (Figure 3.19) were
measured. Starved wild-type mice had an increase in mito-DNA and mito-protein
compared to fed animals. STAT1 protein levels were measured in wild-type mice either
fed or starved and, as expected, we see STAT1 protein levels were decreased during
starvation, Figure 3.20A. No additional increase in mitochondrial biogenesis was seen in
the STAT1 null mice following starvation suggesting that the elevation seen under basal
conditions in these animals was sufficient to deal with the added stress of starvation. This
goes along with the data of the STAT1-/- mice in which the mitochondrial biogenesis
levels are increased in the liver under basal conditions however they do not increase further
under a stressful conditions suggesting that mitochondrial biogenesis is already at maximal
capacity. Alternatively the actions of STAT1 in biogenesis may be limited. Our results
suggest a potential mechanism of how mitochondrial biogenesis is increased under
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starvation. STAT2 levels were unaffected in wild-type mice either fed or starved indicating
that it is not involved in this regulation (Figure 3.20B).
One observation that was made during the starvation experiments was that the
STAT1 knock out mice did not lose their fat pads compared to the STAT1 wild-type mice
after twenty-four hours of starvation (Figure 3.23). We wanted to further explore the
reasoning behind this phenotype because STAT1+/+ and STAT1-/- mice do not have a
difference in body weight, food intake or the amount of weight lost during a twenty-four
hour period (Figure 3.24). We also made the observation that STAT1-/- mice did not
accumulate lipid droplets within the liver during starvation like the STAT1+/+ wild-type
mice (Figure 3.21 and Figure 3.22). This would suggest that the STAT1 knock out mice
do not have the ability to either transfer the lipids from the fat pads to the liver or the mice
have an inability to break down the fat. The rate limiting step of lipolysis within adipose
tissue is phosphorylation of HSL [158]. As can be seen in Figure 3.25, STAT1 knock out
mice have attenuated activation of HSL in the subcutaneous fat after starvation which
would suggest that they are unable to break down fatty acids within the white adipose
tissue. However the basal levels of phosphorylated HSL is seen to be elevated within the
STAT1-/- mice which will need further experiments to understand. It would also be of
interest to look at the amount of glycerol generated from the white adipose tissue during
lipolysis to determine if the defect seen within HSL activation diminishes the ability of
fatty acids to broken down with the glycerol backbone being liberated, which can then
travel to the liver to maintain glucose homeostasis during starvation.
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Because STAT1 knock out mice have a defect in breaking down fat, it was of
interest to determine what their energy source was. We first wanted to look at the
transcription levels of many enzymes that are responsible for fatty acid oxidation and
synthesis. It can be see in Table 3.12 that STAT1 knock out mice have dysregulation of
many of the metabolic enzymes that regulate glycolysis, fatty acid oxidation and fat break
down. This would suggest that STAT1 knock out mice have an inability to switch from
using glucose to fatty acids during starvation once both circulating glucose and glycogen
stores are depleted. This represents a novel role for STAT1 that goes beyond its classical
role within the cell as an antigrowth, anti-viral and pro-apoptotic protein. Similar to what
has been observed here, there are reports that demonstrate a role for STAT1 in regulating
these metabolic enzymes within the confines of a cancer model [102].
Surprisingly, the STAT1-/- mice have an up regulation of glucose within the serum
compared to wild-type mice during starvation which provides evidence that the STAT1-/mice are most likely using gluconeogenesis during starvation. We do not see changes in
cholesterol or triglyercides in the serum, but lactate levels do appear to be changed. To
confirm the hypothesis that STAT1-/- mice have a defect in turning off glycolysis during
starvation more studies are needed, Figure 3.26. The STAT1+/+ and STAT1-/- mice have
the same levels of glycogen and both do not have a problem with depleting their glycogen
stores during starvation, Figure 3.27. It is possible that the STAT1-/- mice have the ability
to use lactate as a substrate for gluconeogenesis during starvation, which would explain
high levels of lactate and the elevated levels of glycolysis enzymes seen in the STAT1-/mice during starvation.
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CONCLUSIONS
This study demonstrates a novel mechanism by which STAT1 and STAT2 control
mitochondrial transcription that is suppressed through the basal circulating levels of IFNβ.
This study is important because it shows two nuclear transcription factors that have the
ability to negatively regulate transcription within the mitochondria in the absence of a
nucleus. This is most likely important for the role of the cell’s response to energy changes
as demonstrated in the metabolic studies done under starvation conditions, and it may also
have anti-viral implications within the cell.
Another interesting finding from this study is that STAT1 plays an important role
within mitochondrial biogenesis. This would be a novel role for STAT1 within the cell and
would suggest that it has the ability to not only negatively regulate mitochondrial
transcription but also negatively regulate mitochondrial biogenesis. It is possible that
STAT1 is controlling mitochondrial biogenesis by simply controlling the transcriptional
regulation of PGC1α. However more studies will be needed to fully understand how this
regulation occurs. One possibility is that STAT1 could bind within the promoter of PGC1α
or it is also possible that it is a component of a macromoecular complex that regulates
PGC1α transcription. The phenotype of the STAT1 knock-out mice seen in this study has
not been reported. The only known phenotype of the STAT1 null mice is that they have a
defect within responding to bacterial and viral infections. More studies will be needed to
fully understand STAT1’s role in energy balance. It will be of interest to look at the energy
source the STAT1-/- mice use during starvation. Also, it will be of interest to look at these
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mice under a western diet considering these mice have more mitochondria within their
livers is it possible that they won’t become obese. The role of STAT1 in regulation of
metabolism is not fully understood, however, the mechanisms are complex and
multilayered. This study also demonstrates a novel role for STATs in metabolism where
they play a vital role in response to changes in homeostasis.
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APPENDIX A
Mitochondrial Encoded mRNAs primers
Primer Name
ND1
ND2
ND3
ND4
ND4L
ND5
ND6
Cytb
COX1
COX2
COX3
ATPase6
ATPase8
12s
16s

Sequence
F 5’-TGCAACTACCCTATCACTCACAC-3’
R 5’-ACGGCTCGTAAAGCTCCGAATAG-3’
F 5’-TACTTCGTCACACAAGCAACAGCC-3’
R 5’-TATGTGCAGTGGGATCCCTTGAGT-3’
F 5’-TGAATGCGGATTCGACCCTACAAGC-3’
R 5’-GCTCATGGTAGTGGAAGTAGAAGAGC-3’
F 5’-ACAGCCTGATTACTGCCACT-3’
R 5’-TCAGTTTGGTTCCCTCATCGGGTA-3’
F 5’-CCATAAGCTCCATACCAATCCC-3’
R 5’-CGCAGGCTGCGAAAACTAAG-3’
F 5’-TATAACCGCATCGGAGACATCGGA-3’
R 5’-TGGAATCGGACCAGTAGGAAAAT-3’
F 5’-TTGGTTGTCTTGGGTTAGCA-3’
R 5’-ACCAATCTCCCAAACCATCA-3’
F 5’-CCCAACAGGATTAAACTCAGATGCAG-3’
R 5’-GGATTGAGCGTAGAATGGCGTATG-3’
F 5’-ACGCCACTTCGCCATCATATTCGT-3’
R 5’-ACATAGGTTGGTTCCTCGAATGTG-3’
F 5’-AAACTGATGCCATCCCAGGC-3’
R 5’-AGGTTAACGCTCTTAGCTTCATAGTG-3’
F 5’-CCAAGGCCACCACACTCCTATTGT-3’
R 5’-GGTCAGCAGCCTCCTATATCATGTG-3’
F 5’-GGATTCCCAATCGTTGTAGCCA-3’
R 5’-AAGGCCTAGGAGATTTGTTGATCC-3’
F 5’-TGCCACAAGTAGATACATCAAC-3’
R 5’-AGGTGCCAGTGGGAATGTTTGTG-3’
F 5’-ACTGGAGCCTTTTCAGCCCTCCT-3’
R 5’-GGATATTGGTGAGTAGGCCAAGGGT-3’
F 5’-ACCCCGAAACCAAACGAGCTACC-3’
R 5’-TGGGTAACCAGCTATCACCAAGCTC-3’
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APPENDIX B
Nuclear encoded ETC mRNA primers
Primer Name
NDUFV1
NDUFS1
NDUFS2
GRIM19
SDHa
SDHb
SDHd
cyc1
Bsc1
COX7a2
COX4i1
Ppa2
ATP5j
ATPaf2

Sequence
F 5ʼ-TGTCTGTGCCACTGAAAGAGCTG-3ʼ
R 5ʼ-ACGGTCTCACACACAGATTTGGG-3ʼ
F 5ʼ-ACAACTGGCACAGCAGCAAGTAAC-3ʼ
R 5ʼ-CAATCTCTACCAGGCACATCCTGC-3ʼ
F 5ʼ-TCGGTGCCATGACTCCTTTCTTC-3ʼ
R 5ʼ-ATGTCATCCAGAAGCCCAAGAGG-3ʼ
F 5ʼ-ATGGACTACAAGCGGAACCTGC-3ʼ
R 5ʼ-TCTCCAGTAGCCAAAGATCAAGGC-3ʼ
F 5ʼ-CCCGATCACATACTGTTGCAGCAC-3ʼ
R 5ʼ-GAGTCGGAGCCTTTCACAGTGTC-3ʼ
F 5ʼ-GTGCGGACCTATGGTGTTGGATG-3ʼ
R 5ʼ-ATTGCCTCCGTTGATGTTCATGGC-3ʼ
F 5ʼ-TGTGTCAGCATTTCTCCAGGACC-3ʼ
R 5ʼ-AGCAGAACACTGACAACCCTCTC-3ʼ
F 5ʼ-GTATGATGATGGCACCCCAGCTAC-3ʼ
R 5ʼ-CATCAACAACATCTTGAGACCCATGC-3ʼ
F 5ʼ-CCTGGAAACCACTTCATTTGGTATCAGG-3ʼ
R 5ʼ-GTCAGTGCCCAGGGCCGTG-3ʼ
F 5ʼ-GAATCTGCTGGCCCTTCGTCAG-3ʼ
R 5ʼ-CATCCCATATCCTCCTGAAACAGCTT-3ʼ
F 5ʼ-AGCCATTTCTACTTCGGTGTGCC-3ʼ
R 5ʼ-CGCCGATCAGCGTAAGTGGG-3ʼ
F 5ʼ-TAGGCTCAAAGTTCTTTCCCGTGG-3ʼ
R 5ʼ-TTAACATCATCAATATCATGAAATTTTTCAGCC-3ʼ
F 5ʼ-CAAAGCGACAGGCATCTGGAGG-3ʼ
R 5ʼ-GACTTCAAATTTGGGATCATCAAATTTGAAGGT-3ʼ
F 5ʼ-GGCTGAGAAAAGGTACGGTATGGAG-3ʼ
R 5ʼ-CAAACTCAATCCCTTGCAGAGCCC-3ʼ
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APPENDIX C
Nuclear encoded mRNAs primers

Primer Name
PGC1α
TFAM
TFB1
TFB2
ISG54
Tubulin
Actin
TOM6
TOM7
TOM20
TOM22
TIM10
TIM22
TIM23
TIM44
POLG
HMG

Sequence
F 5ʼ-CCCTGCCATTGTTAAGACC-3ʼ
R 5ʼ-TGCTGCTGTTCCTGTTTTC-3ʼ
F 5ʼ-GTCCATAGGCACCGTATTGC-3ʼ
R 5ʼ-CCCATGCTGGAAAAACACTT-3ʼ
F 5ʼ-GTATGTCAGCACATCTCCATG-3ʼ
R 5ʼ-CACAAGATCCATCCTGAATGCCA-3ʼ
F 5ʼ-TAGAGCCGTTGCCTGATTCTG-3ʼ
R 5ʼ-ATTCCAGGACCTGGAAAGCA-3ʼ
F 5ʼ-ATGAAGACGGTGCTGAATACTAGTGA-3ʼ
R 5ʼ-TGGTGAGGGCTTTCTTTTTCC-3ʼ
F 5ʼ-CACGGTCATCGATGAAGTTCGC-3ʼ
R 5ʼ-GCACTGGTCAGCCAGCTTGCGATTCC-3ʼ
F 5ʼ-GGTCATCACTATTGGCAACG-3ʼ
R 5ʼ-ACGCATGTCAACGTCACACT-3ʼ
F 5ʼ-CCGCTTCGCCACCGATCGAA-3ʼ
R 5ʼ-TCCATTCTCTGGCTACACCCCTGG-3ʼ
F 5ʼ-TACCTGGGATTTACAAGGGGTGCAG-3ʼ
R 5ʼ-GGATCGCGTCCAAATCCAGATGTTC-3ʼ
F 5ʼ-AGCACAAGGTGACTACGAGAAGGGT-3ʼ
R 5ʼ-ACTGGTGGCGGAAGAGTCTGCT-3ʼ
F 5ʼ-CGCTTCCGGTGTCCTACAGCC-3ʼ
R 5ʼ-TCGTCTAGCTCGTCGTCGTCGT-3ʼ
F 5ʼ-TCCGGAAGTGACCCACGTGCT-3ʼ
R 5ʼ-TTTAGTCCACGGCCTGGGGCAG-3ʼ
F 5ʼ-TGCTGGCCTGTGTAGGAGGGTT-3ʼ
R 5ʼ-TGCAGTTGGTGTCCGGTAAGGGT-3ʼ
F 5ʼ-GCGACCTCATGGAAGGTGGCG-3ʼ
R 5ʼ-ATACCAGTCAGCGGGACGCCG-3ʼ
F 5ʼ-TGGTGACCCGGACAAGGTGC-3ʼ
R 5ʼ-TGCTCTGTGCTGGAGGCTGAGA-3ʼ
F 5ʼ-ACGGGAAGTTGCGGCTGCTC-3ʼ
R 5ʼ-TCACACAAGTCCTCGGTCCGCT-3ʼ
F 5ʼ-ACTACCCAGTCCTGACTCCAA-3ʼ
R 5ʼ-TAGAGCAGTTCGCGTTCTTCC-3ʼ
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Ketothiolase
PTP1b
Glut2
LPK
Glucokinase
PEPCK
SREBP-1
ACC
LCAD
Cpt1b
Cpt1a
Scd-1
FAS

F 5ʼ-TCACGGCAGAAGCAGGATGC-3ʼ
R 5ʼ-TGCTCCATCACTCACCTGACTG-3ʼ
F 5ʼ-ACAGTCGGATTAAATTGCACCA-3ʼ
R 5ʼ-GGGTGAGAATATAGCTCCTCTGG-3ʼ
F 5ʼ-CCTCAAGAGGTAATAATATCCC-3ʼ
R 5ʼ-CCATCAAGAGGGCTCCAGTC-3ʼ
F 5ʼ-CTGGAACACCTCTGCCTTCTG-3ʼ
R 5ʼ-CACAATTTCCACCTCCGACTC-3ʼ
F 5ʼ-CCCTGAGTGGCTTACAGTTC-3ʼ
R 5ʼ-ACGGATGTGGAGTGTTGAAGC-3ʼ
F 5ʼ-GTGCTGGAGTGGATGTTCGG-3ʼ
R 5ʼ-CTGGCTGATTCTCTGTTTCAGG-3ʼ
F 5ʼ-AACGTCACTTCCAGCTAGAC-3ʼ
R 5ʼ-CCACTAAGGTGCCTACAGAGC-3ʼ
F 5ʼ-GATGAACCATCTCCGTTGGC-3ʼ
R 5ʼ-GACCCAATTATGAATCGGGAGTG-3ʼ
F 5ʼ-ATGTTTCTCTGCGATGTTGATG-3ʼ
R 5ʼ-GCTGCCCTCCTCCCGATGTT-3ʼ
F 5ʼ-CAAGTTCAGAGACGAACGCC-3ʼ
R 5ʼ-TCAAGAGCTGTTCTCCGAACTG-3ʼ
F 5ʼ-CTCCGCCTGAGCCATGAAG-3ʼ
R 5ʼ-CACCAGTGATGATGCCATTCT-3ʼ
F 5ʼ-CCGGAGACCCTTAGATCGA-3ʼ
R 5ʼ-TAGCCTGTAAAAGATTTCTGCAAACC-3ʼ
F 5ʼ-AGCGGCCATTTCCATTGCCC-3ʼ
R 5ʼ-CCATGCCCAGAGGGTGGTTG-3ʼ
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